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ABSTRACT 
The rapidly emerging phenomenon of antibiotic resistance is continually 
becoming uncontrollable. Over recent years there have been an alarming increase in 
untreatable multi-drug resistant (MDR) infections that need earnest attention. The 
mechanisms by which antibiotic resistance is achieved in pathogenic bacteria have been 
extensively researched and various alternate treatment or intervention strategies have 
been designed. However, a recently established means of antibiotic resistance observed in 
bacteria is the formation of a physiological state known as Biofilm. 
Biofilm are complex adhesive microbial communities known to habitat animate 
and fomite surfaces. High mortality clinically infectious cases have been associated to the 
biofilms produced by the pathogens. Multiple factors contribute have been indicated to 
interplay the biofilm stimulated antibiotic resistance. These established mechanisms are 
entirely different from canonical antibiotic resistance mechanisms. Thus, biofilm is an 
elusive problem due to its resilient nature. 
Biofilm’s increased resistance to multiple antimicrobials indicate the pressing 
need of alternative natural product therapeutics. Green tea polyphenols (GTP) extracts 
from the leaves of the herbal plant Camellia sinensis, have been attributed to multiple 
health-promoting properties such as anti-inflammatory, anti-tumorigenic, antioxidant, 
antibacterial and antiviral activities. The purified and highly abundant polyphenol 
extracted from green tea, specifically EGCG have been tested for antibacterial properties 
and for anti-biofilm activity on certain bacteria. 
Chemical modification of EGCG has enhanced the green tea beneficial properties. 
This study focusses on utilizing green tea polyphenols as novel synergistic agents with 
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antibiotics to prevent or control biofilm. Purified and chemically modified lipid soluble 
green tea polyphenol and prescribed antibiotics at different concentrations were used to 
study their sole and combinatorial effects on biofilms produced by six different potential 
pathogenic bacteria. The optimal inhibitory combination concentration was determined 
for inhibiting the biofilm formation and reducing the preformed biofilm in each organism 
by more or equal to 90%. Four assays namely Crystal Violet (CV), Colony Forming Unit 
(CFU), Resazurin and Bacterial Live/Dead, were used to derive the best combination and 
correlate with each other to a high extent. These results depict the potential of EGCG-S 
as a synergistic agent with antibiotics and as an antibiofilm agent. 
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INTRODUCTION 
 Antibiotic resistance is a serious global threat spreading at an accelerating pace. It 
is forcing health agencies to recognize it as a pressing priority for intervention (Cohen, 
1992; Sudano Roccaro, Blanco, Giuliano, Rusciano, & Enea, 2004). The early 19th 
century discovery of Penicillin by Alexander Fleming along with Paul Ehrlich’s idea of 
“magic bullets” revolutionized the field of Medicine (Hare, 1983; Aminov, 2010).  This 
exceptional historical event, also known as “Antibiotic Era”, dominated the world due to 
the specific and selective targeting of the pathogens culminating in their fatality. A 
methodical approach for diverse antimicrobial substances screening led to the foundation 
of drug development eventually contributing to birth of multiple antibiotic generations 
(Aminov, 2010).   Nevertheless, the arrival of antimicrobial resistance, aka Post-
Antibiotic Era, has jeopardized the research and therapeutic advances of these 70 years 
successful long period (Wenzel, 2002). 
 Emergence of drug-resistant microbes supports Darwin’s evolutionary theory, 
“Survival of the fittest”, which makes natural drug-resistance a predictable event. Various 
robust mechanisms emerge within microbial communities through the natural 
evolutionary path to nullify the effect of antimicrobials (Holmes et al., 2016). However, 
the unexpected aspect is its acceleration by other factors apart from the natural genetic 
plasticity and microbe adaptability (Palumbi, 2001; WHO, 2016). Alternatively speaking, 
microbe adaptation cannot be controlled but its rate of spread can be influenced 
(Spellberg et al., 2008). A general schematic of antimicrobial resistance development is 
shown in Figure 1 (CDC, 2016a). Incorrect dosage and broad-spectrum antibiotics 
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application has resulted in its abuse and misuse, the main driving force of antimicrobial-
resistant pathogens, aka ‘Superbugs’ (Levy & Marshall, 2004; WHO, 2016).  
Figure 1: Antibiotic resistance. Source: CDC, 2016a. 
 Additionally, existence of selective pressures such as uncertainty in disease 
diagnosis, antibiotic use in hospitals, population dissemination and livestock/agriculture 
application promotes transmission of drug-resistant microbes (Knobler, Lemon, & Najafi, 
2003; Gelband, 2015; Roca et al., 2015). With special reference to bacterial pathogens, 
CDC has determined the ways and their interactions in nature that exposes the human 
population to the infectious agents and are depicted in Figure 2 (CDC, 2016a). This 
global microbial resistance transferal is threatening infectious disease treatments 
(Spellberg et al., 2008). The incessant antibiotics use along with their accumulation in 
environment (Wellington et al., 2013) has propelled recurrence of drug-insensitive 
microbe infections (Gelband, 2015; Roca et al., 2015).  
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Figure 2: Transmission of Antibiotic Resistance. Source: CDC, 2016a 
 CDC in 2013, published list of major drug-resistance bacteria that are threat in 
USA which is continually apprised costing us both human lives and productivity loses  
(Gelband, 2015; CDC,2016b). The CDC has categorized the infectious pathogens based 
on the hazard/threat level and the detailed information is presented in Figure 3 and 4 
(CDC, 2016b).  In United States, annually at least 2 million people suffer from drug-
resistant bacterial infections and at least 23,000 people lead to death due to their 
debilitating infections (CDC, 2016b). The persistent risk of emergence of multi-drug 
resistant bacteria and the alarming increase in untreatable infections need earnest 
attention (Blair et al., 2015; Bos et al., 2015). It is critical to gather knowledge of novel 
virulence mechanisms employed by pathogens to become antibiotic resistant as it will 
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enable development of effective and innovative broad-spectrum antibiotics or drug 
combinations to combat these fatal infections (Lin et al., 2015).  
Figure 3 and 4: Classification of pathogenic bacteria according to hazard level. 
Source: CDC, 2016b 
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 The anti-drug resistant phenotype development is based on modulation of 
multiple host factors such as resistance degree expression, toleration to resistance 
mechanisms and location of colonization site (Giedraitienė, Vitkauskienė, Naginienė, & 
Pavilonis, 2011). There are various accessory drivers that play a role in the emergence of 
antimicrobial resistant forms and their interactions at a societal level is a cause of 
concerns. The different drivers and their extent of involvement is displayed in Figure 5 
(Holmes et al., 2016). Overall the emergence of resistance, it’s transmission and the 
difficulties faced during reversal of this resistance at different levels suggests no single 
Figure 5: Antimicrobial resistance drivers. Source: Holmes et al., 2016 
and sure solution to this health problem (Holmes et al., 2016). Thus, a combination of 
various policies associated with development of novel antimicrobials and their adequate 
implementation is necessary (Laxminarayan et al., 2016). Formulation of these policies 
depend on the insights into resistance mechanisms, novel therapeutic approaches and 
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influence of resistance drivers in community and environment (Årdal et al., 2016; Dar et 
al., 2016; Mendelson et al., 2016).  
 Antimicrobials have ruled the field of medicine successfully for last 80 years and 
the impact of rise in the resistant forms is a complex and multifaceted urgent public 
health concern (Lammie & Hughes, 2016; Laxminarayan et al., 2016). The mechanisms 
for antibiotics resistance are broadly classified into two categories, namely, inherent and 
acquired mechanisms of resistance both of whose origins can be genetic and/or 
biochemical defects (Blair et al, 2015). The intrinsic resistance is the innate ability of 
bacteria to tolerate the influence of single or combination of antibiotics. The intrinsic 
resistance is associated with presence of genes on bacterial chromosomes and their 
vertical propagation to the progeny. The acquired resistance pertains to resistance 
developed on secondary exposure to susceptible antimicrobials. It is mediated by 
acquisition of exogenous DNA molecules through transformation, conjugation or 
transduction, horizontal gene transfer shown in Figure 6 (Levy, 1998; Potera, 2013). 
Additionally, the mobile elements transposons and integrons are also implicated in 
resistance development (Giedraitienė, Vitkauskienė, Naginienė, & Pavilonis, 2011). This 
entire set of genes exhibiting the ability to move through related or unrelated bacterial 
species is now termed as mobile resistome or mobilome (Wellington et al., 2013). 
 This mobile resistome exists either on bacterial chromosomes or plasmid extra- 
chromosomes (Dever, 1991) and is either generated by spontaneous mutations, adaptive 
mutagenesis and hyper-mutations (intrinsic)or obtained from foreign source and inserted 
into chromosomal DNA (acquired). The spontaneous type pertains to random  
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Figure 6: Antibiotic resistance by horizontal gene transfer systems. Source: Potera, 
2013. This picture shows the three popular ways the bacteria obtain mobile resistome (A) 
Conjugative plasmid DNA transfer, (B) Transduction, viral DNA delivery and (C) 
Transformation, uptake of naked DNA.  
generation of mutations in the chromosome due to errors in DNA replication or repair 
pathways. Such growth-dependent mutations provide resistance to structurally similar 
antibiotics by complete insensitivity, decline in affinity and influencing antibiotic uptake 
efflux systems (Rice & Bonomo, 2011). The hyper-mutations are induced by a small 
bacterial population known as hyper-mutators, which represents a short-duration state 
characterized with exceptionally high rate of mutability. This stage can be independent or 
dependent of the selective antibiotic pressure (Martinez & Baquero, 2000). The adaptive 
mutagenesis mainly occurs in non-dividing or slow-dividing cells under antibiotic 
selection. Most of the times the terms hyper-mutator and adaptive mutations are used 
interchangeably (Erill, Campoy, Mazon, & Barbe, 2006). 
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 The antibiotic insensitivity can be attributed specifically to (i) Target 
modification: Alteration of targets by genetical mutations or pots-translational 
modifications(ii) Efflux and Influx pumps: Involvement of genetically coded membrane 
porins for antibiotic extrusion or decreased uptake and (iii) Antibiotic Inactivation or 
modification: Innate expression of biomolecules that negate the antibiotic effect (Silva, 
1996; Forbes, Sahm, & Weissfeld, 1998; Giguère, Prescott, Dowling, Baggot, & Walker, 
2006; McCallum, Berger-Bächi, & Senn, 2010; Giedraitienė, Vitkauskienė, Naginienė, & 
Pavilonis, 2011; Blair et al, 2015; Wright, 2016). 
 The interaction between an antibiotic and its target is specific with high binding 
affinity. Any minute changes in target affects antibiotic binding but not target’s function 
and thus acts as means of resistance development. The basis for target modification is 
both genetic and non-genetic. Bacterial population obtains random genes from the 
environment carrying mutation that makes the target coding allele insensitive to the drug. 
Uptake of mosaic genes coding for homologues of Penicillin-Binding Proteins (PBPs) 
inhibits the action of antibiotics that target the peptidoglycan in cell wall. The 
homologues alter the structure of peptidoglycan in a way that it is no longer susceptible 
to the drugs. This mechanism is employed by Methicillin-Resistant Staphylococcus 
aureus (MRSA). The mechanism of producing antibiotic resistant target molecules that 
resembles PBP is also known as By-pass mechanism of antibiotic inhibition. Similarly, 
protein and DNA synthesis inhibition is also prevented by spontaneous or acquired 
mutations of genes implied in these pathways like Ribosomal RNA (rRNA), DNA gyrase 
etc. The non-genetic way of altering the target is by modifying or protecting it. The target 
is modified by addition of chemical group or attaching with other substances to 
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camouflage it thus preventing its degradation. For instance, 16SrRNA is methylated 
protecting its binding to Macrolides. Sometimes, the entire regulatory pathway like LPS 
production is modulated to develop resistance to Polymyxin B (McCallum, Berger-Bächi, 
& Senn, 2010; Giedraitienė, Vitkauskienė, Naginienė, & Pavilonis, 2011; Blair et al., 
2015; Wright, 2016). 
 The second type is restricting access to targets by perturbing the permeability of 
the pathogen. Variations observed in the composition of cell wall make Gram negative 
organisms less antibiotic less susceptible than Gram positive. Impermeability of the outer 
membrane makes the targets inaccessible by limiting the uptake of antibiotics. Any 
molecule depending on its chemical composition utilizes one of the three transport 
options in Gram negative microbes: (i) Diffusion across membrane, (ii) diffusion through 
porins and (iii) self-promoted uptake. The porins, membrane protein channels, are used 
for most molecules transport. Therefore, down regulation of these channels, influx pumps 
or replacement by highly-selective channels limits the antibiotics entry. In contrast to 
reduced cell permeability, there is existence of efflux pumps that contributes to increased 
permeability. Efflux pumps are membrane proteins that uptake the single or multiple 
antibiotics with their simultaneous expulsion to main low intracellular concentration thus 
preventing antibiotic and target reaction. (McCallum, Berger-Bächi, & Senn, 2010; 
Giedraitienė, Vitkauskienė, Naginienė, & Pavilonis, 2011; Blair et al, 2015; Wright, 
2016). Emergence of multiple drug resistant (MDR) microbes is chiefly due to the 
complex multidrug efflux system comprising of various family of proteins that need to be 
targeted to make pathogens sensitive (Lin et al., 2015). 
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 The third mechanism for antibiotic resistance is modification or inactivation of 
antibiotics. The microbes produce enzymes that can modify the antibiotic structurally or 
functionally thus resisting their action. This inactivation of the target can occur by 
hydrolysis, by chemical group transfer or by redox process involving β-lactamase, 
transferases and oxido-reducatses. Many organisms utilize single or combination of these 
enzymes to develop resistant against multiple antibiotics (Giedraitienė, Vitkauskienė, 
Naginienė, & Pavilonis, 2011; Blair et al., 2015; Wright, 2016). These mechanisms are 
widely dispersed in multiple bacterial genuses and their contribution to microbe virulence 
is depicted in Figure 7 (McCallum, Berger-Bächi, & Senn, 2010; Arias & Murray, 2012; 
Sriramulu, 2013; Wright, 2016). 
 Another recently established means of antibiotic resistance developed by 
pathogenic bacteria is the formation of a physiological state known as Biofilm (Wright, 
2016). In last few years a group of bacterial pathogens known as ESKAPE (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter spp.) has grasped lot of attention from 
scientific community due to the high mortality biofilm-induced clinical infections (Rabin 
et al., 2015b).  
 Additionally, the Biofilm is implicated in multiple human diseases either due to 
inherent susceptibility or contraction through contaminated medical devices (Fux, 
Costerton, Stewart, & Stoodley, 2005; Hall, McGillicuddy, & Kaplan, 2014). National 
Institute of Health has indicated that 80% of clinical microbial infections involve biofilms 
(Davies, 2003). There are chronic diseases like Cystic fibrosis (Costerton, 1999) caused 
by bacterial pathogen that has biofilm producing ability along with dental plaque (Hojo, 
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Nagaoka, Ohshima, & Maeda, 2009), wound infections (James et al., 2008) and medical 
devices infection such as urinary catheter, prosthetic joints and cardiac valve infections 
(Khardori & Yassien, 1995; Tenke, Kovacs, Jäckel, & Nagy, 2006; Matthews, Berendt, 
McNally, & Byren, 2009). The infections formed by biofilm are highly difficult to 
diagnose and treat due to their antimicrobial resistance and heterogeneous composition. 
Thus, there is enormous interest in studying the biofilms structurally and functionally to 
elucidate their resistance mechanisms for devising effective therapeutics (Rabin et al., 
2015a). 
Figure 7: Antibiotic resistance mechanisms. Source: Sriramulu, 2013 
 Numerous studies have elucidated and identified the processes and mechanisms 
resulting in biofilm formation and its associated antimicrobial resistance. Biofilm is a 
multifaceted complex microbial association. Soto (2013) has aptly defined the term 
biofilm as “a microbiologically derived sessile community characterized by cells that are 
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irreversibly attached to a substratum or interface or each other, are embedded in a matrix 
of extracellular polymeric substances that they have produced and exhibit an altered 
phenotype with respect to growth rate and gene transcription.” (p.223). Understanding the 
mechanisms of resistance in biofilms accentuate the need to familiarize with biofilm 
formation process (Høiby, Bjarnsholt, Givskov, Molin, & Ciofu, 2010).  
 Formation of bacterial biofilms is tightly-regulated processes independent of host 
factors (Stewart, 2002). There are three main stages involved in biofilm development: (i) 
Adhesion or attachment, the bacterial cells (planktonic) contact the biotic or abiotic 
surfaces and adhere. At this stage the adhesion is reversible and the bacterial community 
is susceptible to antimicrobials; (ii) Growth and maturation, the bacterial multiply along 
with production of extracellular polymer matrix. The bacterial aggregates mature to form 
microcolonies resulting in firmer and irreversible attachment. During this stage, the 
phenotype and physiological state of bacterial cells undergoes transformation from 
planktonic cells to sessile cells stage. This stage is also known for its remarkably high 
tolerance to multiple antibiotics; (iii) Detachment or dispersion, the sessile bacterial 
communities undergo dissolution to form planktonic cells and liberate them allowing 
spread of infection to different locations. Both active and passive processes such as 
secretion of biofilm degrading enzymes, quorum sensing and external fluid shear or 
abrasion respectively are implicated in the detachment stage (Høiby, Bjarnsholt, Givskov, 
Molin, & Ciofu, 2010; Soto,2013; Van Acker, Van Dijck, & Coenye, 2014). The 
schematic representation of biofilm formation is depicted in Figure 8. 
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 Figure 8: Development of bacterial biofilm. Source: Vasudevan, 2014 
 Biofilm provides a survival advantage to bacteria against various harsh 
environmental conditions allowing development of resistance to most antimicrobial 
treatment.  In comparison to planktonic cells, the biofilm is 10,000 times more resistant 
to antimicrobial compounds (Rabin et al., 2015a; Cheng et al., 2016). The conventionally 
characterized antibiotic resistance mechanisms in planktonic cells no longer applies to the 
biofilm indicating the later has different and its own mechanisms working in conjunction 
with the conventional ones (Estela & Alejandro, 2012). Literature suggests that the 
biofilm resistance is more due to adaptive alterations than genetic changes. Genetic 
alterations are facilitated by spontaneous mutations induced by biofilm matrix protection 
and horizontal DNA transfer mediated by bacterial close spatial proximity (Stewart, 
2002). 
 Many years of research have identified the role of numerous mechanisms for 
biofilm antimicrobial resistance and all these mechanisms work in cohesive manner. The 
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characteristic high resistance to antimicrobials in biofilm structures is attributed to 
various intrinsic processes such as (i) Limited antibiotics penetration, the extracellular 
matrix, EPS, a complex mixture of proteins, polysaccharides and DNA provides 
structural stability and acts as barrier for bacterial biofilms. This protective layer prevents 
diffusion of antibiotics thus making it ineffective; (ii) Antibiotic neutralization, the 
biofilm may consist of single or varied bacterial species that allows accumulation of 
antibiotic degrading or modifying enzymes. These enzymes are specialized proteins that 
confer antibiotic resistance; (iii) Biofilm heterogeneity, the aerobic and anaerobic 
processes make biofilms structurally and metabolically heterogeneous leading to 
resistible to antimicrobials; (iv) Microenvironment alteration and reduced growth rate, 
the establishment of required active biomolecules concentration gradient affects growth 
of bacteria. The nutrients-deprived zones form slow-growing or stationary phases of 
bacterial communities. These communities are metabolically inactive that decreases cell 
membrane permeability interfering with antibiotics as most antimicrobials target the 
growth phase of bacteria; (v) Persistent non-replicative bacterial population, the biofilm 
environment stimulates a subpopulation of bacteria to form ‘persister’ cells. These cells 
are not mutators but remain inactive and resistant to antibiotics after prolonged exposure. 
These act as disease reservoirs and can mediate reinfection leading to its persistence; (vi) 
Adaptive responses, various environmental stresses such as temperature, pH fluctuations, 
oxidative stress and DNA damage causes physiological modifications that provide 
protection against the harmful antibiotic effects. This is facilitated by induction of efflux 
pumps, membrane proteins alterations, quorum sensing molecules and phase variations 
(Stewart, 2002; Høiby, Bjarnsholt, Givskov, Molin, & Ciofu, 2010; Estela & Alejandro, 
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2012; Soto,2013; Rabin et al., 2015a). The pictorial presentation of the role played by all 
the resistance mechanisms in biofilm physiology is depicted in Figure 9. 
Figure 9: Antimicrobial resistance mechanisms in biofilm. Source: Drenkard, 2003 
 All genuses of bacteria employ the adaptive responses for their survival. The drug 
efflux is one of the main mechanisms for antibiotic resistance and the pumps are 
stimulated for expelling the antibiotics or toxic compounds at increased rate. Depending 
on bacteria and environmental condition, the pumps are either constitutively or 
intermittently expressed and might target multiple antibiotics simultaneously. There is 
wide existence of six family of bacterial efflux pumps in the entire bacterial domain and 
are categorized as (i) the ATP-binding cassette (ABC) superfamily; (ii) the major 
facilitator superfamily (MFS); (iii) the multidrug and toxic compound extrusion (MATE); 
(iv) the small multidrug resistance (SMR) family; (v) the resistance-nodulation-division 
(RND) superfamily; (vi) the drug metabolite transporter (DMT) superfamily. Membrane 
porins can be modified or mutated to reduced or completely abolish the permeability of 
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the antimicrobials compounds. Quorum sensing molecules are utilized by bacteria to 
inter-communicate effectively to alter gene expression. This differential gene expression 
facilitates upregulation of virulence factors making the bacteria pathogenic. Phase 
variation is also known to prevent antibiotic susceptibility by constant fluctuations in 
planktonic cells and biofilm phenotypes (Stewart, 2002; Høiby, Bjarnsholt, Givskov, 
Molin, & Ciofu, 2010; Estela & Alejandro, 2012; Soto,2013; Van Acker, Van Dijck, & 
Coenye, 2014; Rabin et al., 2015a).  
 The rapid emergence of antimicrobial sensitivity among several microbes and its 
dissemination is rendering the current antibiotic therapy ineffective. This situation is 
worsened by establishment of biofilm as it makes biofilm effective eradication very 
difficult.  The adaptability of the bacteria under the harshest conditions by biofilm 
formation makes bacterial infections a pressing global concern. The multiple mechanisms 
conferring antibiotic resistance and the interplay of them has renewed interest to 
investigate alternative therapeutic ways for treating debilitating bacterial infections. The 
scientific community has over-exploited the entire repertoire of natural and synthetic 
antibiotics. Besides, numerous reports have indicated antimicrobial activity of various 
natural medicinal compounds against planktonic and monospecies biofilms. Therefore, 
natural products could possibly be used in combination with the antibiotics to overcome 
this problem (Cheng et al., 2016, Karygianni et al., 2016).  
 So far various natural product alternatives including cumin, ginger and tea 
polyphenols have been researched and tested (Cheng et al., 2016). However, the tea 
polyphenols are identified as the most promising anti-infective candidate, specifically 
polyphenols derived from green tea (Daglia, 2012). One of the main causes of antibiotic 
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resistance emergence is their misuse and overuse. Therefore, several investigations have 
proposed the use of polyphenols in conjunction with antibiotics. Implementing this 
combination therapy is expected to potentiate their efficacy, lower therapeutic dose and 
prevent the adverse counter-reactions (Lin, Chin, Hou, & Lee, 2008; Coutinho, Costa, 
Lima, Falcão-Silva, & Siqueira Júnior, 2009).  
 Green tea leaves are the products of plant scientifically known as Camellia 
sinensis. Overall four main varieties of tea exist namely, white, green, oolong and black 
depending on the extent of fermentation and color development.  Green tea is 
unfermented version and postulated to be most beneficial of all varieties. The main 
component of green tea that provides it with its health benefits is its natural polyphenols 
(Chan, Tie, Soh, & Law, 2011; Reygaert, 2014).  Flavonoids are the highly abundant 
polyphenols out of which catechins are significantly important due to their broad-
spectrum beneficial properties with special reference to antimicrobial activity (Reygaert, 
2014). There are four distinct types of catechins namely, Epigallocatechin-3-gallate 
(EGCG), Epigallocatechin (EGC), Epicatechingallate (ECG) and Epicatechin (EC) 
(Noormandi & Dabaghzadeh, 2015). EGCG is a major component constituting 59% of 
green tea catechins (Forester & Lambert, 2011; Fournier-Larente, Morin, & Grenier, 
2016). Figure 10 shows the molecular structure of the different catechins.   
 EGCG is the most abundant catechin and have been attribute to various health-
promoting benefits. However, the stability of EGCG has raised concerns about its 
bioavailability (Mereles & Hunstein, 2011; Widyaningr, Fudholi, Sudarsono & 
Setyowati, 2015). Thus, EGCG has been modified to yield highly stable, lipid-soluble 
analogue with improved bioavailability (Yang, Landis-Piwowar, H. Chan, & P. Dou, 
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2011). Recently, an esterified derivative of EGCG was synthesized, isolated and purified 
with the help of high-speed countercurrent chromatography the structure was determined. 
This modification is performed on the naturally existing water-soluble EGCG. The 
esterification of fatty acid makes EGCG lipophilic and enables increased absorption by 
lipid bilayer. Figure 11 presents the esterified EGCG, EGCG-Stearate, commonly known 
as EGCG-S.  This altered EGCG has been indicated as a promising antibacterial, antiviral 
and anti-spore agent (Chen, Dickinson & Hsu, 2009; Hsu, 2012).  
Figure 10: Green tea catechins structure. Source: Perumalla and Hettiarachchy, 2011 
 Green tea, especially EGCG and its derivatives are widely popular for their 
several beneficial properties such as anti-inflammatory, anti-oxidant, anti-carcinogenic, 
anti-viral, anti-bacterial, anti-amyloidogenic and anti-biofilm (Bieschke et al., 2010; Xu, 
Zhou, & Wu, 2010; Serafini et al., 2011; Steinmann, Buer, Pietschmann, & Steinmann, 
2013; Serra, Mika, Richter, & Hengge, 2016). Despite all the broad spectrum protective 
effects, the mechanisms underlying the EGCG’s mode of action are still elusive. The 
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possible interactions of EGCG with varied biomolecules and their resultant effect on 
several signal transduction pathways are postulated to be responsible for EGCG 
effectiveness (Steinmann, Buer, Pietschmann, & Steinmann, 2013).   
Figure 11: Lipid soluble EGCG derivative, EGCG-Stearate. Source: Hsu, 2012 
 The modified versions of the polyphenols have been postulated to have higher 
synergistic effect compare to the original polyphenols (Hsu, 2012). Nonetheless, the 
mechanisms underlying these health-promoting effects are still elusive. So far numerous 
research conducted on green tea polyphenols have indicated their ability to target vast 
array of biomolecules such as cell membrane/cell wall components and several proteins 
like enzymes, porins and so on. There are several modes of action accredited to EGCG’s 
antibacterial activity however, according to Erbil & Digrak, 2013, any natural product 
exerts its inhibitory antibacterial activity majorly through four-broad means namely, (i) 
additive or synergistic effect with antimicrobial; (ii) Inhibiting bacterial enzymes; (iii) 
Repression of efflux pumps; (iv) microbial adherence interference.  
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Various specific target molecules and the mechanisms for EGCG action are 
summarized in Table 1. There exist multiple accessory mechanisms by which EGCG 
might be exerting or enhancing its antibacterial activity. These mechanisms are 
summarized in Table 2. 
Table 1: Principle Mechanisms exhibited by EGCG on bacteria 
Cellular targets Mechanisms Involved Reference 
H2O2 production Auto-oxidation leading to 
oxidative stress 
Smith, Imlay, & Mackie, 
2003 
Induction of pro-oxidant agents 
resulting in disruption/lysis of 
outer membrane of Gram negative 
bacteria 
Arakawa et al., 2004; Betts 
& Wareham, 2014; 
Noormandi & 
Dabaghzadeh, 2015 
β-lactamase 
inactivation 
 
Direct inhibition of 
β-lactamase 
secretion or 
penicillinase 
activity 
Exogenous and endogenous 
Reactive Oxygen Species 
production, high oxidative stress 
 
Cui et al., 2012a 
 
 
Yam, Hamilton-Miller & 
Shah, 1998; Sugita-Konishi 
et al., 1999; Zhao et al., 
2002; Osterburg et al., 
2009; Noormandi & 
Dabaghzadeh, 2015 
Interference with 
glycocalyx and cell 
wall-cell 
membrane 
interactions 
Inhibit the polysaccharides 
interaction in glycocalyx and 
hydrophobic interactions by 
affecting microbial enzymes, 
nutrient deprivation and 
suppression of signaling proteins 
phosphorylation 
Blanco, Sudano-Roccaro, 
Spoto, Nostro, & Rusciano, 
2005; Ratnasooriya, 
Ratnasooriya, & 
Dissanayake, 2016 
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Inhibition of 
peptidoglycan 
formation 
Suppression of PBP2 (Penicillin 
binding protein) and obstruction 
of PBP2 binding sites by tea itself 
Yam, Hamilton-Miller & 
Shah, 1998; Zhao et al., 
2001; Zhao, Asano, Hu, & 
Shimamura, 2003; 
Osterburg et al., 2009; 
Koech, Wanyoko, & 
Wachira, 2014; Noormandi 
& Dabaghzadeh, 2015 
Physical 
disruption of lipid 
bilayer 
 
Impaired cell 
membrane 
integrity 
Cell membrane leakage and 
electrostatic interactions induction 
 
 
Fatty acid synthesis inhibition by 
suppressing fatty acid synthesis 
enzymes 
Ikigai, Nakae, Hara, & 
Shimamura, 1993; 
Hamilton-Miller, 1995; 
Caturla, Vera-Samper, 
Villalain, Mateo, & Micol, 
2003; Yamamoto, 
Yanagawa, Hara, & 
Shimamura, 2003; 
Arakawa et al., 2004; 
Zhang and Rock, 2004; 
Tamba et al., 2007; Bikels-
Goshen, Landau, Saguy, & 
Shapira, 2010; Gordon & 
Wareham, 2010; Reygaert, 
2014; Anita, Sivasamy, 
Madan Kumar, Balan, & 
Ethiraj, 2015  
DNA gyrase 
inhibition 
Nonfunctional or Absence of 
DNA gyrase interferes with DNA 
replication and transcription. 
Gradisar, Pristovsek, 
Plaper, & Jerala, 2007; 
Bikels-Goshen, Landau, 
Saguy, & Shapira, 2010; 
Gordon & Wareham, 2010; 
Anita, Sivasamy, Madan 
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Kumar, Balan, & Ethiraj, 
2015 
Suppression of 
ATP synthase 
machinery  
Essential for cell growth or 
viability 
Reygaert, 2014 
Interference with 
bacterial 
gelatinase activity 
Important in host invasion Bikels-Goshen, Landau, 
Saguy, & Shapira, 2010; 
Sudano Roccaro, Blanco, 
Giuliano, Rusciano, & 
Enea, 2004; Blanco et al., 
2003 
Inhibition of 
Amylase, LDH, 
Glycolytic enzymes 
and 
glucosyltransferase 
activity 
Crucial in the transport and 
metabolism of carbohydrates  
Hattori et al., 1990; Otake 
et al., 1991; Hirasawa et 
al., 2006; He, Lv & Yaoa, 
2007; Xu et al., 2011; 
Anita, Sivasamy, Madan 
Kumar, Balan, & Ethiraj, 
2015 
Inhibition of 
collagenase 
activity 
Important virulence factor in 
periodontal disease 
Makimura et al., 1993; 
Sakanaka, Aizawa, Kim, & 
Yamamoto, 1996 
Suppression of 
dihydroflolate 
reductase activity 
Play role in synthesizing purines 
and pyrimidines 
Chung et al., 2003; Radji, 
Agustama, Elya, & 
Tjampakasari, 2013 
Affect agmatine 
deiminase system 
(AgDS) function  
Compromises the competitive 
fitness of bacteria 
Xu et al., 2011 
Make protein non-
functional  
Interaction distort the tertiary 
protein structure compromising 
the function 
Schultz, Hunter & Appel, 
1992; Nagayama, 
Iwamura, Shibata, 
Hirayama, & Nakamura, 
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2002; Yoda, Hu, 
Shimamura, & Zhao, 2004; 
Xu et al., 2011; Anita, 
Sivasamy, Madan Kumar, 
Balan, & Ethiraj, 2015 
  
Table 2: Accessory Mechanisms exhibited by EGCG on bacteria 
Mechanisms Involved Reference 
Complexes with proteins and 
polysaccharides 
Smullen, Koutsou, Foster, Zumbé, & Storey, 
2007 
Induction of Heat Shock proteins 
(HSP) 
Bikels-Goshen, Landau, Saguy, & Shapira, 2010 
Inhibition of multidrug resistance 
P-glycoprotein 
Stapleton & Taylor, 2002 
Inhibition of Tetracycline efflux 
pumps  
Sudano Roccaro, Blanco, Giuliano, Rusciano, & 
Enea, 2004 
Blocks conjugated R plasmid or 
DNA transfer 
Lee et al., 2005 
Suppress release of toxins and 
periplasm proteins like maltose 
binding proteins 
Sugita-Konishi et al., 1999 
Induce cellular defense proteins Cho, Schiller, Kahng, & Oh, 2007 
Down regulate elongation factor 
(EF-2) in protein translation 
Binds to Iron or reduces Iron 
availability 
Smullen, Koutsou, Foster, Zumbé, & Storey, 
2007; Anita, Sivasamy, Madan Kumar, Balan, & 
Ethiraj, 2015 
Bind to the fimbriae inhibiting 
bacterial adherence 
Sakanaka, Aizawa, Kim, & Yamamoto, 1996 
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Lead to DNA cleavage, DNA 
scission and anti-topoisomerase I 
& II activity 
Kiran et al., 2010 
Interfere with qorum-sensing 
activities 
Vattem, Mihalik, Crixell, & McLean, 2007; 
Kiran et al., 2010 
Immunomodulatory and 
immunostimulatory agents 
Monobe, Ema, Kato, & Maeda-Yamamoto, 
2008; Kiran et al., 2010 
Regulating the inflammatory 
response 
Lee et al., 2005; Noormandi & Dabaghzadeh, 
2015 
 In addition to the mechanistic details, the entire concept of green tea’s 
antimicrobial activity has been exploited to expand the horizons of the green tea 
beneficiary properties. There exist strong evidences of the ability of green tea 
polyphenols to synergistically enhance the antibiotics effect on bacteria when used in 
combination. The synergism of green tea polyphenols is observed in both in vitro 
bacterial cultures and in vivo mice models. Several research on Staphylococcus aureus 
(particularly MRSA), Staphylococcus epidermidis, and Escherichia coli with different 
antibiotics have been performed. For instance, green tea catechins show synergistic 
action with (i) Tetracyline against Staphylococcus aureus and Staphylococcus 
epidermidis (Sudano Roccaro, Blanco, Giuliano, Rusciano, & Enea, 2004; Fanaki, 
Kassem, Fawzi & Dabbous 2008); (ii) Penicillin against Staphylococcus epidermidis 
(Haghjoo et al., 2013); (iii) Penicillin, oxacillin, ampicillin/sulbactam, and imipenem 
against Methicillin Resistant Staphylococcus aureus (MRSA) (Hu, Zhao, Hara & 
Shimamura, 2001; Hu, Zhao, Yoda, Asano, Hara & Shimamura, 2002; Zhao, Hu, Okubo, 
Hara, & Shimamura, 2001; Stapleton, Shah, Hara, & Taylor, 2006; Aboulmagd, Al-
Mohamme, & Al-Badry, 2011); and (iv) Chloramphenicol, ciprofloxacin, and cefotaxime 
against antibiotic resistant Escherichia coli isolates like extended-spectrum beta-
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lactamase (ESBL) producers (Fanaki, Kassem, Fawzi & Dabbous 2008; Cui et al., 2012a; 
Passat, 2012). The green tea polyphenols synergy with β-lactam antibiotics is attributed 
to its ability to interfere with bacterial cell wall integrity by binding to peptidoglycan. 
Additionally, the use of green tea polyphenols in synergistic studies results in decreasing 
the MIC thus allowing use of low concentrations of antibiotics and combatting antibiotic 
resistance infections (Hu, Zhao, Yoda, Asano, Hara & Shimamura, 2002). Similar studies 
could be applied to bacteria biofilm infections to evaluate the potential of green tea 
polyphenols in inhibiting biofilms synergistically with antibiotics.  
 Apart from antibiotic resistance infections, there have been comparatively fewer 
studies in regards to green tea polyphenols exhibiting anti-biofilm activity. Various types 
of green tea polyphenols, especially have been tested successfully as anti-biofilm agents 
on multiple bacteria like Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus mutans, Escherichia coli, Enterobacter faecalis and Propinobacterium 
gingivalis (Blanco, Sudano-Roccaro, Spoto, Nostro, & Rusciano, 2005; Xu, Zhou, & Wu, 
2010; Asahi et al., 2014). A recent publication indicated EGCG’s potential to inhibit the 
biofilms formed by highly infectious Escherichia coli strains. This study showed EGCG 
to interfere with amyloid fibers synthesis and assembly along with cellulose production, 
key drivers of biofilm formation (Serra, Mika, Richter, & Hengge, 2016).  Taking into 
consideration the facts and scientific data, the potential of using green tea polyphenols as 
synergistic agents with antibiotics could be immense enabling enhancement of 
antibacterial activity (Slobodníková, Fialová, Rendeková, Kováč, & Mučaji, 2016). 
 Modern genomics tools have implicated differential expression of a wide range of 
genes for biofilm formation. The gene sets experiencing up or down regulation vary 
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among bacterial species. The mechanisms attributed to EGCG-S action could be either by 
inhibition of antibiotic resistance development or suppression of biofilm formation or 
combination of both. This prediction is based on the studies of EGCG’s effect on 
antibiotic (Tetracycline) efflux pumps and biofilm genes such as ica operon involved in 
slime morphology and adhesion conducted in Staphylococcus aureus (Sudano Roccaro, 
Blanco, Giuliano, Rusciano, & Enea, 2004; Blanco, Sudano-Roccaro, Spoto, Nostro, & 
Rusciano, 2005).  
 Another study performed in Bacillus subtilis indicated EGCG’s interaction with 
cell surface membrane proteins. This resulted in identification of four membrane proteins 
namely, Oligopeptide ABC transporter binding lipoprotein, glucose phosphotransferase 
system transporter protein, phosphate ABC substrate binding protein and penicillin 
binding protein 5 due to their sparse expression (Nakayama et al., 2015). In 
Streptococcus mutans EGCG have been shown to alter the activity of enzymes such as 
glucosyltransferases (GTFs) necessary in polysaccharide synthesis, a component of 
biofilm matrix in addition to various accessory cariogenic virulence factors like agmatine 
deiminase system (AgDS), F1Fo-ATPase system, enolase and lactate dehydrogenase (Xu, 
Zhou & Wu, 2011; Xu, Zhou & Wu, 2012). A research published recently demonstrated 
the anti-biofilm ability of EGCG in virulent strains of Escherichia coli by suppressing 
csg operon coding for amyloid curli fibers, interfering the assembly of fiber’s subunits 
and repressing genes involved in cellulose synthesis (Serra, Mika, Richter, & Hengge, 
2016).  
 The recent advances provide insights into the potential role of EGCG as broad 
spectrum anti-biofilm and synergistic agent with antibiotics. EGCG derivative, EGCG-S, 
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probably can enhance this potential further and this study focuses on evaluating that 
potential. For the synergistic study a diverse group of bacteria comprising of Gram 
positive (G+) organisms such as Staphylococcus aureus, Staphylococcus epidermidis and 
Bacillus megaterium, Gram Negative (G-) organisms like Escherichia coli and 
Pseudomonas aeruginosa and an Acid Fast (AF) species representative Mycobacterium 
smegmatis will be used.  The rationale for the choice of organisms is based on their 
potential pathogenicity, developing antibiotic resistance and biofilm production. The use 
of such a heterogeneous group additionally facilitates deciphering the molecular mode of 
action of EGCG-S as an anti-biofilm and antibiotic synergistic agent. 
Objectives  
I. Determine the Lethal Dose (LD50) for both antibiotics and tea polyphenols 
individually on biofilm formed by Staphylococcus epidermidis, Staphylococcus 
aureus, Pseudomonas aeruginosa, Escherichia coli, Mycobacterium smegmatis and 
Bacillus megaterium. 
II. Study the synergistic effect of EGCG-S with antibiotics on formation of biofilm in six 
bacterial spp. 
III. Study the synergistic effect of EGCG-S with antibiotics on inhibition of preformed 
biofilm (Biofilm reversal) in six bacterial spp. 
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MATERIALS AND METHODS 
1. Culturing Bacteria 
 Multiple bacterial strains, Staphylococcus epidermidis, Staphylococcus 
aureus, Bacillus megaterium, Pseudomonas aeruginosa, Escherichia coli and 
Mycobacterium smegmatis were used in this study and thus proper culturing techniques 
were applied to begin the experiment with pure cultures.  Invariably each strain is 
maintained on a solid medium such as tryptic soy agar, nutrient agar and any selective 
medium like blood agar (if available) as a stock plate. Additionally, lyophilized pure 
cultures and glycerol stocks were also preserved at -80oC. The glycerol stocks were 
prepared by autoclaving 30% glycerol solution to which broth or liquid bacterial culture 
was mixed in 1:1 ratio (Prakash, Nimonkar, & Shouche, 2013, Alam et al., 2015). 
 For routine use the stock plates for all bacteria were stored in a refrigerator 
or cold room at 4oC. These were checked for contamination regularly and fresh overnight 
cultures were prepared before starting every experiment. The overnight cultures were 
checked for purity using simple or Gram stain.  A small size of the bacterial inoculum 
was added into a fresh broth tube aseptically using a cotton swab or wire loop.  The tube 
was labeled properly with name of bacteria and cultured date, and incubated in a shaking 
incubator at 37oC and 250 rpm (Tuomanen et al., 1986).  The next day, their purity was 
checked again using simple or gram stain before beginning the experiment. If there was 
any presence of contamination, discontinuous streaking method was applied to isolate the 
pure colony followed by continuous method to make new stock plate. Both streaking 
methods require incubation at 37oC for 24 hours.  
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  Two types of plating techniques were used for bacterial isolation namely, 
discontinuous and continuous streaking method. Discontinuous method, shown in Figure 
12, was used to isolate a single colony from the culture based on the colony 
morphological characteristics whereas continuous, shown in Figure 12, was used to make 
a master stock plate once the. desired pure colony of bacterial strain was obtained. The 
purity of the culture was ensured by conducting simple staining and/or Gram staining 
procedures.  
Figure 12: Microbiological Streaking Methods. (A) discontinuous and (B) continuous  
2. Media Preparation  
 The standard media used in the experiments were prepared following the 
manufacturer’s instructions. Nutrient agar and tryptic soy agar was used for bacterial 
stock cultures and tryptic soy broth with no and 0.1% Sucrose was used to conduct the 
experiments. Nutrient agar (DifcoTM) is prepared by dissolving 23 grams (g) of the 
powder into 1 liter (L) of sterile deionized water (DI H2O) in a 2 L flask. The nutrient 
broth powder was weighed to 8g and was dissolved into 1 L of sterile DI H2O for 
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preparation of nutrient broth (Wards).  Six mL of nutrient broth were then dispensed into 
glass test tubes prepared in a rack.  For tryptic soy agar (DifcoTM), 40g were dissolved 
into 1 L of sterile DI H2O, and 30g of tryptic soy broth (Wards) were dissolved into 1 L 
of sterile DI H2O.  The tryptic soy broth was supplemented with 1g of sucrose in 1L to 
give final sucrose concentration as 0.1%.  All media were thoroughly mixed using a 
magnetic stir bar and hot plate.  The media were then autoclaved for 15 to 20 minutes at 
121oC using the liquid setting.  Once autoclaved, the agar was allowed to cool to room 
temperature. At proper temperature, it was poured into sterile plates aseptically and 
allowed to solidify.  All media were stored in a cold room at 4oC for future use. 
3. Staining Techniques 
a. Simple Stain 
  At the beginning of every experiment, the fresh overnight culture was used 
to perform simple staining to ensure the absence of contamination. Using a sterile cotton 
swab a small amount of culture is obtained and spread on the microscope slide making 
three gradients lines.  The smear was dried, heat fixed and stained with a drop of 
monochrome stain such as methylene blue for 1 minute so the cells can absorb the stain. 
Cover slip was then placed onto the stained sample before blotting using bibulous paper. 
The slide was observed under oil immersion at 1000x total magnification for cell 
morphologies (Lee et al., 2015).  
b. Gram Stain 
 A bacterial culture smear was prepared and stained with crystal violet for 
20 seconds. The dye was then rinsed with sterile deionized water for two seconds 
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followed by addition of Gram’s iodine for one minute. The slide was rinsed again with 
Gram’s decolorizer or 95% alcohol for 10-20 seconds.  The sample was then washed with 
tap water before and after safranin counterstaining for one minute.  A cover slip was 
placed on top of the stained sample and blotted with a bibulous paper.  The sample was 
observed under oil immersion at 1000x total magnification (Lee et al., 2015). 
4. Preparation of treatment agents 
a. Green Tea polyphenols (EGCG-S) 
   All green tea polyphenols were purchased from Camellix LLC, Augusta, 
GA. The tea polyphenols were prepared based on their solubility. EGCG-S was dissolved 
in absolute ethanol (EtOH).  A stock concentration of 1% (10,000μg/ml) was prepared 
and diluted to the desired concentration needed for each experiment.   
Calculation for the master stock solution: 
1% = 10mg/mL = 0.01g of EGCG-S + 1mL of EtOH. 
b. Antibiotics  
There were two main antibiotics used in this study namely, Erythromycin and 
Tetracycline. The powders were purchased from Sigma Aldrich. A stock concentration of 
1000μg/ml was prepared by dissolving the appropriate amount of both antibiotics in 
absolute ethanol. The solutions were then sterilized through filtration and stored at -20°C 
for further studies. 
Calculation for the master stock solution: 
1000μg/mL = 1mg/mL= 0.001g of Antibiotic/s + 1mL of EtOH 
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5. Effect of Antibiotics and Green Tea Polyphenols (GTPs) on Bacterial biofilms 
a. Semi-quantitative determination of LD50 for antibiotics and GTPs and optimal 
combination concentration by Crystal Violet (CV) Assay 
The fresh overnight cultures were prepared in tryptic soy broth.  Dilution 
of the cultures using the liquid media was carried out to adjust the absorbance to 0.2 
Optivcal Density (O.D) at 600nm using a spectrophotometer (Yoon et al., 1994). The 
diluted culture was then incubated at 37°C for 3-4 hours to catch the logarithmic 
phase of growth. This assay was conducted in two ways: 
(i)  The effect of Antibiotics and EGCG-S on biofilm formation: 
Two 24-well plates were used and setup as shown in Figure 13.  Here, in 
each well tryptic soy broth with 0.1% sucrose, log phase culture and treatments were 
added along with positive and negative control. Samples are treated with different 
concentrations of antibiotics and EGCG-S. Once the plate was setup it was incubated 
for 3-4 days at 37°C. After the incubation, one plate was used for CV assay and other 
plate was used for CFU assay to determine viability. the liquid from each well was 
pipetted out carefully without disturbing the biofilm attached on the surface of the 
plate. This was followed by rinsing the wells with 1mL of 1X Phosphate Buffered 
Saline (PBS) after which 0.1% Crystal Violet (0.1g of CV powder + 100mL of 70-
95% EtOH) stain was added to the first plate. The plate was incubated at room 
temperature for 24 hours to maximize the staining. After 24 hours, the crystal violet 
is pipetted out, followed by 1X PBS wash and air dried by inverting for 24 hours. 
The next day the walls of the wells were cleaned with sterile cotton swabs soaked in 
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1X PBS to reduce the background signal. Once the excess amount of CV was 
removed, 30% Acetic acid solution is added to each well. The plates were swirled 3-
4 times to lift the attached cells and/or biofilm. The solution from each well is pipetted 
out and put in sterile cuvette for absorbance readings. The absorbance was performed 
at 595nm with 30% Acetic acid as a blank (Nowak et al., 2015). The percent (%) of 
inhibition was calculated for each treatment according to the following formula: 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =
(𝑂. 𝐷 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂. 𝐷 𝑜𝑓 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
𝑂. 𝐷 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙
 × 100% 
Control 
(+) 
EGCG-S 
Conc. 1 
(A1) 
EGCG-S 
Conc. 2 
(A2) 
EGCG-S 
Conc. 3 
(A3) 
EGCG-S 
Conc. 4 
(A4) 
EGCG-S 
Conc. 5 
(A5) 
Antibiotic 
Conc. 1 
(B1) 
A1+B1 A2+B1 A3+B1 A4+B1 A5+B1 
Antibiotic 
Conc. 2 
(B2) 
A1+B2 A2+B2 A3+B2 A4+B2 A5+B2 
Antibiotic 
Conc. 3 
(B3) 
A1+B3 A2+B3 A3+B3 A4+B3 A5+B3 
Figure 13: 24-Well LD50 Determination. * Concentration of Antibiotic and 
EGCG-S varies according to organism 
For CFU determination, 100μL of sterile deionized water was dispensed in 
each well and the biofilm attached to the plate’s surface was separately scrapped 
using loops. The mixture was mixed by pipetting it up and down. The samples from 
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each well were transferred to microfuge tubes and stored at 4°C for CFU and 
Live/Dead assays. 
(ii) The effect of antibiotics and EGCG-S on pre-formed biofilm: 
Two 24-well plates were used and setup as shown in Figure 13.  Here, in each 
well tryptic soy broth with 0.1% sucrose and log phase culture were added along with 
positive and negative control. Once the plate was setup it was incubated for 3-4 days 
at 37°C. For evaluating the effect of treatments (antibiotics and EGCG-S) on the 
formed biofilm, they were added on the 4th day and plate was incubated for 24 hours 
at 37°C (Nowak et al, 2015). On the fifth day, after the incubation, the protocol 
described in the section 5a(i) was exactly followed.   
b. Quantitative determination of optimal combination concentration by Colony 
Forming Unit (CFU) Assay 
The overnight cultures were prepared and a 24-well plate was setup as 
shown in Figure 13 following the protocol described in the section 5a(ii) was 
followed till the stage of biofilm scrapping. A serial dilution technique was 
performed with the single or combination treatment. After the scrapping, samples 
from each well are subjected to dilution. The dilution factors of 104 were plated on 
the tryptic soy agar plate using sterile plate spreading method. The flow chart of 
serial dilutions was carried out as depicted in Figure 14. The plates were dried for 
10 minutes at room temperature and placed for incubation at 37°C for 24 hours 
(Dastgheyb et al., 2014). After 24 hours, the colonies were counted to determine the 
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CFU/mL for each sample. The percent (%) of inhibition was calculated for each 
treatment according to the following formula: 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =
(𝐶𝐹𝑈 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐶𝐹𝑈 𝑜𝑓 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
𝐶𝐹𝑈 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙
 × 100% 
The CFU assay was conducted in the same manner for both inhibition of biofilm 
formation and preformed biofilm. 
                            Figure 14: Serial Dilution chart 
c. Fluorescence based Quantitative Resazurin Assay 
Fresh overnight cultures were prepared in tryptic soy broth.  The cultures 
were then diluted with same broth to an absorbance range of 0.2-0.3 O.D at 600nm 
using a spectrophotometer (Yoon et al., 1994). The culture was incubated at 37°C 
for 3-4 hours to catch the log phase and was used to setup the experiment. A clear 
flat bottom 96-well plate was setup as shown in Figure 15. Once the plate was setup 
it was incubated for 3-4 days at 37°C. After the incubation, the liquid from each well 
was pipetted out carefully without disturbing the biofilm attached on the surface of 
100
• Biofilm scrappings obtained after either antibiotic or tea or 
combination treatment
10-1
• 10 μl of 100 + 90 μl of Broth
10-2
• 10 μl of 101 + 90 μl of Broth
10-3
• 10 μl of 102 + 90 μl of Broth
10-4
• 10 μl of 103 + 90 μl of Broth
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the plate. Next, the wells were rinsed with 100μL of 1X Phosphate Buffered Saline 
(PBS). The fluorescence reaction was initiated by 120μL addition of 200μM 
Resazurin solution (Original 2mM Stock, 5mg of Resazurin powder + 10mL of 1X 
PBS, diluted to working stock of 200μM) stain was added to the plate. The plate was 
covered with aluminum foil and left at 4°C for 24 hours. The following day 
fluorescence was measured with excitation and emission wavelength of 560nm and 
590nm respectively using Microplate reader adjusted to the fluorescent mode. The 
Relative Light Units (RLU) were measured and the percent (%) of inhibition was 
calculated for each treatment according to the following formula: 
% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =
(𝑅𝐿𝑈 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑅𝐿𝑈 𝑜𝑓 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡)
𝑅𝐿𝑈 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙
 × 100% 
Control 
(+) 
  Tea 
Conc. 2 
  Combo 
3 
  Combo 
11 
  
Control (-)   Tea 
Conc. 3 
  Combo 
4 
  Combo 
12 
  
Antibiotic 
Conc. 1 
  Tea 
Conc. 4 
  Combo 
5 
  Combo 
13 
  
Antibiotic 
Conc. 2 
  Tea 
Conc. 5 
  Combo 
6 
  Combo 
14 
  
Antibiotic 
Conc. 3 
  Tea 
Conc. 6 
  Combo 
7 
  Combo 
15 
  
Antibiotic 
Conc. 4 
  Tea 
Conc. 7 
  Combo 
8 
  Combo 
16 
  
Antibiotic 
Conc. 5 
  Combo 
1 
  Combo 
9 
  Combo 
17 
  
Tea Conc. 
1 
  Combo 
2 
  Combo 
10 
  Combo 
18 
  
Figure 15: 96-well plate set up for Resazurin Assay *Concentration of Antibiotic and 
EGCG-S varies according to organism 
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d.  Fluorescence based Qualitative Microscopic Live/Dead Assay 
 The overnight was made and prepped as in the above experiments. For this 
assay, 6 Well plate/s was setup, as shown in Figure 16. After the setup, the plate 
was subjected to similar incubation conditions as discussed in the above 
experiments for both biofilm formation and pre-formed biofilm. The company 
manufactured LIVE/DEAD® BaclightTM Bacterial Viability Kit (L13152) was used 
for this assay.  The kit comprises of two fluorescent dyes, A (Syto®9-Green) and B 
(Propidium iodide-Red) which need to be dissolved in 2.5mL sterile DI H2O 
individually in dark. Both dye solutions were mixed in the ratio of 1:1and 
transferred to an Eppendorf tube. The tubes were always covered in aluminum foil 
to limit light exposure and stored in the freezer until further use. After incubation of 
6 well plate, the supernatant is removed and the well is rinsed with 1X PBS. Once 
the wells are devoid of any liquid, 10μL of the dye mixture was added in the center 
of each well. A coverslip was placed in each well and the plate was wrapped with 
aluminum foil and incubated for 24 hours in the dark at room temperature before 
viewing under a ZEISS fluorescent microscope at 1000x total magnification (ZEISS 
Axio Scope.A1).  Green fluorescence indicated viable cell with its intact cell 
membrane whereas red fluorescence indicated the cell was dead due to its damaged 
cell membrane (Tawakoli et al., 2012). 
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Positive Control 
Antibiotic 
Concentration 
Tea concentration 
Combination 
Concentration 1 
Combination 
Concentration 2 
Combination 
Concentration 3 
Figure 16: 6 Well plate set up for Live/Dead Assay*Concentration of Antibiotic 
and EGCG-S varies according to organism 
The microscopic observation for the LIVE/DEAD® BaclightTM Bacterial 
Viability Assay was performed on a ZEISS Axio Scope.A1 fluorescence 
microscope.  In fluorescent mode, two dials (one below the eyepiece and one on the 
bottom right side of the scope) were switched to setting #3 for GFP.  The 
fluorescent light (right side of scope) was turned on, and the switch on the top right 
side of the scope was flipped towards the eyepiece.  Low power (100x), high power 
(400x), and oil immersion (1000x) were used to view the sample.  For camera use, 
the Zeiss Zen program was viewed on a DELL computer and the switch on the top 
right side of the scope was flipped away from the eyepiece. Images were majorly 
captured at oil immersion (1000X).   
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RESULTS AND DISCUSSION 
 In this study, 6 microorganisms were used Gram-positive Bacteria: Staphylococcus 
epidermidis (S. epidermidis), Staphylococcus aureus (S. aureus) and Bacillus megaterium 
(B. megaterium); Grm-negative Bacteria: Escherichia coli (E. coli) and Pseudomonas 
aeroginosa (P. aeroginosa); and Acid Fast Bacteria: Mycobacterium smegmatis (M. 
smegmatis). Different experiments were performed sequentially to determine the optimal 
minimum inhibitory concentration of antibiotics and tea polyphenol (EGCG-S) and their 
combination on the bacterial biofilms. For each bacterium, the following experimental 
regime was followed. The results are described as per each organism. 
I. Establishing the optimal combination of antibiotics and Tea polyphenols 
Characterization of microbes based on its simple stain, gram stain and special 
stain (Acid-fast for M. smegmatis) 

Determining the optimal inhibitory combined concentration of antibiotics and tea 
polyphenols on bacterial growth 
A. Inhibiting biofilm formation 
Studying the inhibitory effect of multiple concentrations of antibiotics and tea 
polyphenols (EGCG-S) individually on biofilm formation 

Checkerboard Assay to determine the optimal combination of antibiotics and tea 
polyphenols on biofilm formation (using CV, CFU and Resazurin assay) 
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B. Inhibiting pre-formed biofilm 
Profiling the effect of various concentrations of Antibiotics and Tea Polyphenols 
separately on preformed biofilm 
 
Checkerboard Assay to determine the optimal combination of antibiotics and tea 
polyphenols on preformed biofilm (using CV, CFU and Resazurin assay)  
II. Fluorescence Microscopic analysis to visualize the inhibitory effect  
i. BacLight Assay on treatments targeting biofilm formation process. 
ii. BacLight Assay on treatment targeting preformed biofilm. 
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I. Staphylococcus epidermidis 
A. Identification of S. epidermidis by staining techniques 
Simple and Gram stains were conducted to identify the morphology of the 
bacterium, shown in Figure 17.  Both stains confirmed the morphology of S. 
epidermidis as spherical or cocci shaped. The Gram stain indicated the bacterium to 
be Gram positive with evenly sized violet or purple colored cocci dispersed in the 
smear.  
Figure 17: S. epidermidis staining. (A) Simple stain at 1000x (B) Gram stain at 1000x. 
B. Determining the optimal inhibitory combined concentration of antibiotics and 
tea polyphenols on bacterial growth 
  This experiment was carried out to test the effect of multiple 
concentrations of antibiotic (tetracycline) and tea polyphenol (EGCG-S) on 
bacterial growth along with certain combined treatments (antibiotic + tea). A CFU 
assay was carried out on the samples to estimate the extent of inhibition 
quantitatively. Figure 18 shows the percentage inhibition of single and combined 
treatments on S. epidermidis growth. The CFU analysis data, depicted in Table 3, 
was used to determine individual lethal dose (LD50) for both antibiotics and tea 
polyphenol. Based on the results, TE15 and TE40 resulted in 50% inhibition. 
Additionally, the tea polyphenol concentration giving 50% inhibition are ES50 and 
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ES100 (For eg. ES50 = EGCG-S 50 μg/mL and so on). Further testing of multiple 
combinations indicated that the TE15+ES100 and TE15+ES250 both gave about 
95% inhibition from which a combination having low concentrations of tetracycline 
and EGCG-S was chosen for further studies. 
Table 3: CFU analysis of antibiotic and tea concentrations on 
growth of S. epidermidis 
 
Cells/mL   % Inhibition Std. Dev. 
PC 27455000 0 0 
NC 0 100 0 
TE10 14900000 45.71667673 0.311073793 
TE15 13355000 51.30275636 1.323047199 
TE30 15800000 42.4698189 0.45404538 
TE40 12640000 53.99273332 0.776696201 
ES50 11995000 56.26022276 1.227362594 
ES100 11125000 59.48605605 0.169231673 
ES150 7425000 72.98662203 0.756365811 
ES250 6415000 76.62492639 0.234345395 
TE10+ES50 8260000 69.86654373 1.172451716 
TE10+ES100 7670000 72.00160316 1.513239881 
TE10+ES250 3675000 86.6087297 0.140373814 
TE15+ES50 1715000 93.76522765 0.289378632 
TE15+ES100 1315000 95.21437049 0.098630629 
TE15+ES150 2385000 91.33358837 0.502932438 
TE15+ES250 1525000 94.4384856 0.170756453 
TE30+ES50 2720000 90.09139654 0.036321748 
TE30+ES100 2270000 91.72115478 0.263833873 
TE30+ES150 2360000 91.40279832 0.032274494 
TE30+ES250 1870000 93.1882307 0.015280735 
TE40+ES50 4000000 85.39464381 0.883374276 
TE40+ES100 4865000 82.24510186 0.85720831 
TE40+ES250 4025000 85.30222633 0.916674702 
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Figure 18: Percentage Inhibition of multiple treatments on S. epidermidis growth 
C. Determining the optimal combination of antibiotics and tea polyphenols to 
inhibit biofilm formation  
  Once the optimal combination concentration for inhibiting the S. 
epidermidis growth was determined, this experiment was conducted to observe the 
inhibitory effects of single and combination treatments on biofilm production. It 
was designed to serve two purposes namely, (i) to establish the LD50 for antibiotic 
and tea polyphenol respectively and (ii) to estimate the extent of inhibition of 
TE15+ES100 combination on biofilm production. For consistency of the data this 
experiment was carried out independently using three different assays namely, CV, 
CFU and Resazurin assay. The results from CV assays are indicated in Table 4, 5 
and Figure 19 and 20. The data obtained showed that single antibiotic or tea 
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polyphenols treatments gave maximum inhibition of 58%. Further testing certain 
combinatorial treatments indicated that the optimum combination concentration 
(TE15+ES100) inhibiting the bacterial growth only resulted in 73% inhibition of 
biofilm formation. This clearly suggests that this bactericidal combination 
concentration is not sufficient to inhibit the biofilm formation effectively. Thus, 
different concentration with increasing antibiotic and/or tea polyphenol 
concentration was tested to determine the optimal combination that can provide a 
maximum inhibition of biofilm formation. From the results, it is observed that 
combination of TE15+ES250 effectively inhibits biofilm production by 97%. 
 
 
Table 5: Inhibitory effect of Combined 
Concentration of Tetracycline and EGCG-
S on S. epidermidis biofilm formation (CV 
assay)  
Avg % 
Inhibition 
Std 
Dev. 
NC 0 0 
PC 100 0 
TE15+ES50 51.80317324 1.371561 
TE15+ES100 73.71523524 0.62427 
TE15+ES200 86.81297476 0.37527 
TE15+ES250 97.51133301 0.689462 
TE15+ES500 66.07729927 0.429199 
TE30+ES50 57.99645716 0.617917 
TE30+ES100 90.30456179 0.935792 
TE30+ES200 72.16411565 0.559192 
TE30+ES250 77.94499918 0.545145 
TE15+ES500 54.23701299 0.436202 
TE40+ES50 49.51186392 0.488183 
TE40+ES100 62.92641714 0.518866 
TE40+ES200 81.15892755 0.123742 
TE40+ES250 65.25688148 0.700003 
TE40+ES500 48.72120804 0.716896 
Table 4: LD50 determination for 
Tetracycline and EGCG-S on S. 
epidermidis biofilm formation (CV 
assay) 
   
Avg % 
Inhibition 
Std Dev. 
PC 0 0 
TE15 56.60320639 1.425781 
TE30 53.7293766 1.464383 
TE40 51.6078484 0.698603 
ES50 46.39572305 1.203734 
ES100 53.36629633 0.472514 
ES200 44.7852917 1.63915 
ES250 38.89611874 1.001039 
ES500 9.995277392 1.271014 
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Figure 19: Percentage Inhibition of multiple single treatments on S. epidermidis 
biofilm formation. 
Figure 20: Percentage Inhibition of multiple combination treatments on S. 
epidermidis biofilm formation. 
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  Quantitative CFU assay, data shown in Table 6 and Figure 21, and 
fluorescence-dye based spectrophotometric assay (Resaurin assay), data shown in 
Figure 22, 23 and Table 7, was conducted. The Resazurin assay determines the 
viability of the sample based on fluorescence property exhibited by Resazurin 
compound, a bluish purple colored dye. This dye is metabolically converted into a 
pink colored fluorescent product which is then excited to record the measurement. 
The fluorescence recorded is the direct measure of cellular metabolic activity of 
bacteria. This assay has recently become popular for screening anti-bacterial or 
anti-biofilm agents effectively. The results from CFU assay correlates with that of 
the CV assay however, Resazurin assay is more sensitive approach. The optimal 
combination of TE15+ES250 from CV and CFU assay yielded 95-97% inhibition. 
On the contrary, the Resazurin assay identified TE15+ES200 as optimal 
combination due to its ability to inhibit biofilm formation by 99% and TE15+ES250 
inhibited approximately 98%. This discrepancy can be attributed to semi-
quantitative nature of CV and manual biofilm scrapping performed for CFU assay. 
Both these methods are easy and inexpensive to conduct but are highly prone to 
error. Additionally, there two major disadvantages with CV assay: (i) inability to 
distinguish between live and dead bacterial cells and (ii) occasionally, bacterial 
cellular aggregates result in false positives. Thus, to increase the sensitivity of the 
assay and to reflect the true potential of the single or combination treatments the 
Resazurin assay was utilized. Based on fluorometric data, the combination of 
TE15+ES200 gives the maximum inhibitory effect ~99% followed by TE15+ES250 
resulting in 98% inhibition.  
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Table 6: CFU analysis of antibiotic and tea concentrations on 
S. epidermidis biofilm formation 
 Avg Cells/mL Avg % Inhibition Std. Dev 
PC 4723333 0 0 
TE15 2100000 55.5205151 0.578985 
TE30 2033333 56.9484876 0.084285 
TE40 2166667 54.1192972 0.273468 
ES50 3146667 33.3648797 0.46364 
ES100 2353333 50.1985624 0.661999 
ES200 2510000 46.8642308 0.139628 
ES250 2833333 40.0402316 0.781156 
ES500 4226667 10.5287012 0.404626 
TE15+ES50 2203333 53.3513028 0.025413 
TE15+ES100 1336667 71.6875312 0.396155 
TE15+ES200 478333 89.8726864 0.008513 
TE15+ES250 218667 95.3561146 0.430293 
TE15+ES500 1713333 63.7184786 0.230408 
TE30+ES50 1976667 58.1408605 0.303963 
TE30+ES100 423000 91.0427873 0.050035 
TE30+ES200 1343333 71.5594489 0.005506 
TE30+ES250 1016667 78.4575222 0.542278 
TE30+ES500 2313333 51.0406309 0.5187 
TE40+ES50 2356667 50.0910452 0.443027 
TE40+ES100 1796667 61.9870221 0.751649 
TE40+ES200 881667 81.3224119 0.340727 
TE40+ES250 1656667 64.9108516 0.450086 
TE40+ES500 2376667 49.6733553 0.271351 
  
63 
 
Figure 21: Percentage Inhibition of S. epidermidis biofilm formation (CFU assay) 
Figure 22: Fluorescence measurements on treatment of S. epidermidis biofilm 
formation (Resazurin assay) 
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Table 7: Inhibition of S. epidermidis biofilm formation by single or 
combination treatments using Resazurin assay 
 Avg RLU Std. Dev Avg % Inhibition Std. Dev 
PC 2483.802 141.7169 0 0 
NC 0 0 100 0 
TE10 1647.696 100.5598 33.66989844 0.264063 
TE15 1059.226 34.51247 57.32482908 1.045392 
TE30 1229.099 41.46545 50.48246499 1.15586 
TE40 1172.181 18.42508 52.75126199 1.954036 
TE50 2290.91 79.49365 7.707094728 2.065423 
ES25 2321.891 14.3578 6.349768692 5.921407 
ES50 1693.893 80.0162 31.78328081 0.670683 
ES100 1112.312 27.21513 55.17566141 1.461813 
ES150 1177.386 35.80789 52.56134034 1.265025 
ES200 1312.249 60.85715 47.1516257 0.56518 
ES250 1518.186 39.31797 38.82210784 1.907618 
ES500 2235.109 107.3494 9.989400145 0.813706 
TE15+ES50 791.854 17.86152 68.08784962 1.101674 
TE15+ES100 640.0625 46.01215 74.24145501 0.382797 
TE15+ES150 1018.186 18.0192 58.96087417 1.616078 
TE15+ES200 20.0075 42.95462 99.24258444 1.686174 
TE15+ES250 40.3395 42.86411 98.42256195 1.635743 
TE15+ES500 81.813 77.77467 96.79024355 2.948138 
TE30+ES50 865.8345 57.09392 65.14960977 0.310211 
TE30+ES100 223.537 59.90326 91.05445084 1.901355 
TE30+ES150 715.909 33.65121 71.09118306 3.004261 
TE30+ES200 873.3075 51.10331 64.841358 0.051436 
TE30+ES250 1146.06 31.36514 53.74734963 3.901799 
TE30+ES500 995.6825 100.6984 59.96345906 1.76986 
TE40+ES50 333.572 27.22785 86.57953339 0.330493 
TE40+ES100 1645.165 30.25498 33.69108311 2.56526 
TE40+ES150 510.499 52.49136 79.47375125 0.942192 
TE40+ES200 401.072 66.65754 83.90285638 1.765244 
TE40+ES250 1531.746 22.85581 38.25636191 2.602678 
TE40+ES500 735.2505 37.32039 70.39285691 0.186728 
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Figure 23: Percentage Inhibition of S. epidermidis biofilm formation (Resazurin 
assay) 
D. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Finally, another fluorescent dye based microscopic analysis is performed 
to elucidate the optimal combination concentration and confirm the findings. This 
assay qualitatively identifies the viable and nonviable bacterial cells using 
fluorescent dyes exploiting the biochemical changes in the cellular membrane’s 
integrity. The microscopic images are illustrated in Figure 24. The control sample 
had a green fluorescence indicating that the bacterial cells in the biofilm were alive.  
On treating the biofilm, there is significant increase in red fluorescence suggesting 
that the cells were dead. Based on the CV, CFU and Resazurin assay results, 
different combinations were tested to determine and confirm the most consistent 
one which in this case is TE15+ES250 due to the significant number of non-viable 
cells in the biofilm. 
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 Figure 24: Live and Dead Assay of S. epidermidis biofilm formation. (A) Control (B) 
with TE15 (C) ES100 (D) TE15+ES200 (E) TE15+ES250, and (F) TE30+ES100 
  In conclusion, the results from all the four assays described above are 
considered and confirmed to determine the optimal concentrations of antibiotic and 
tea polyphenols to have synergistic anti-biofilm effect on biofilm formation process. 
Thus, the biofilm formation in case of S. epidermidis, an opportunistic pathogen, is 
inhibited by a combination of Tetracycline 15 ug/mL and EGCG-S 250 ug/mL. 
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E. Determining optimal combination of antibiotics and tea polyphenols to inhibit 
pre-formed biofilm 
  Once the optimal combination concentration for inhibiting the S. 
epidermidis growth and biofilm formation was determined this experiment was 
conducted to observe the inhibitory effects of single and combination treatments to 
reduce. It was designed to serve two purpose namely, (i) to establish the LD50 for 
antibiotic and tea polyphenol respectively and (ii) to estimate the extent of 
inhibitory effect of TE15+ES100 combination on pre-formed biofilm. For 
consistency of the data this experiment was carried out independently using two 
different assays namely, CV and CFU assay. The results from CV assays are 
indicated in Table 8, 9 and Figure 25 and 26. The data obtained showed that single 
antibiotic or tea polyphenols treatments gave maximum inhibition of 58%. Further 
testing of certain combinatorial treatments indicated that the inhibitory combination 
concentration (TE15+ES100) for bacterial growth only resulted in 61% inhibition. 
This clearly suggests that the current combination is not sufficient to inhibit the 
biofilm formation effectively. Thus, increasing concentrations of antibiotic and/or 
tea polyphenol were tested to determine the optimal combination that can provide a 
maximum reduction of pre-formed biofilm. From the results, it is observed that 
combination of TE15+ES250 effectively reduced the biofilm to 96%. The optimal 
combination concentration obtained from CV assay was confirmed using the 
quantitative CFU assay. The data is represented in Figure 27 and Table 10. The 
CFU assay supported the CV data indicating that the combination of TE15+ES250 
effectively yields 96% reduction of formed biofilm.  
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Table 8: LD50 determination of 
Tetracycline and EGCG-S on S. 
epidermidis pre-formed biofilm (CV 
assay) 
   Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
TE15 56.62446268 0.313253 
TE30 54.20674967 0.27468 
TE40 40.26541407 0.92859 
ES50 45.07760088 0.564514 
ES100 48.45655798 1.015648 
ES200 57.56457231 0.193944 
ES250 47.4173512 0.151091 
ES500 35.71447706 0.925908 
  
 
 
Figure 25: Percentage Inhibition of multiple single treatments on S. epidermidis 
preformed biofilm. 
Table 9: Inhibitory effect of Combined 
Concentration of Tetracycline and 
EGCG-S on S. epidermidis pre-formed 
(CV assay) 
 Avg % 
Inhibition 
Std. 
Dev. 
TE15+ES50 31.75172 0.392611 
TE15+ES100 61.71921 1.013656 
TE15+ES200 90.25009 0.216846 
TE15+ES250 96.00668 0.576519 
TE15+ES500 44.82047 0.28206 
TE30+ES50 54.93393 1.0616 
TE30+ES100 90.22904 0.617822 
TE30+ES200 68.72044 0.368799 
TE30+ES250 70.02839 1.094761 
TE30+ES500 50.30933 0.00524 
TE40+ES50 51.67731 0.480555 
TE40+ES100 88.42788 0.75034 
TE40+ES200 59.75252 0.471011 
TE40+ES250 44.40944 0.219429 
TE40+ES500 21.88487 0.521809 
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 Figure 26: Percentage Inhibition of multiple combination treatments on S. 
epidermidis pre-formed biofilm (CV Assay). 
Figure 27: Percentage Inhibition of multiple combination treatments on S. 
epidermidis pre-formed biofilm (CFU Assay). 
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Table 10: CFU analysis of antibiotic and tea concentrations on S. 
epidermidis pre-formed biofilm 
 
Avg Cells/mL Avg % Inhibition Std. Dev. 
PC 7085000 0 0 
TE15 3250000 54.11929719 0.27346827 
TE30 3150000 55.52051512 0.57898471 
TE40 4130000 41.6842368 0.70576556 
ES50 3915000 44.74902665 0.19779507 
ES100 3670000 48.25157233 1.52984109 
ES200 3050000 56.94848757 0.08428526 
ES250 3730000 47.34261755 0.32739955 
ES500 4635000 34.60407308 0.71706007 
TE15+ES50 4825000 31.94309674 1.33755209 
TE15+ES100 2755000 61.11151043 0.10532129 
TE15+ES200 705500 90.04310672 0.02284314 
TE15+ES250 307500 95.64644105 0.40089856 
TE15+ES500 3955000 44.19656584 0.56006641 
TE30+ES50 3240000 54.24737945 0.66411706 
TE30+ES100 669500 90.54433463 0.18316868 
TE30+ES200 2200000 68.87890586 2.08101307 
TE30+ES250 2130000 69.9627633 0.78595656 
TE30+ES500 3450000 51.33023859 0.73767254 
TE40+ES50 3455000 51.22272137 0.36735387 
TE40+ES100 759500 89.23775582 1.26857088 
TE40+ES200 2830000 60.03384247 0.67639984 
TE40+ES250 3915000 44.74902665 0.19779507 
TE40+ES500 5565000 21.46840371 0.437521 
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F. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Fluorescence-based Live and Dead Assay was also conducted to 
qualitatively study the effects of combination treatments on pre-formed biofilm.  
Results for S. epidermidis treated with multiple combinations are illustrated in 
Figure 28.  The control sample had a green fluorescence indicating that the bacterial 
cells were alive.  On treatment, the cells emitting red fluorescence increased 
suggesting that the cells were no longer viable. Based on the microscopic images, 
the optimal combination concentration was determined to be TE15+ES250. 
  In conclusion, the results of the CV assay, CFU viability study, 96-well 
microplate Resazurin assay and Bacterial viability assay indicate that EGCG-S at 
250 ug/mL has the highest synergistic effect on Tetracycline 15 ug/mL for 
inhibiting both biofilm formation and pre-formed biofilm. These results are indicative 
of the potential of antibiotic and tea polyphenol combination as an anti-biofilm agent. 
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Figure 28: Live and Dead Assay of S. epidermidis pre-formed biofilm. (A) Control (B) 
with TE15 (C) ES250 (D) TE15+ES200 (E) TE15+ES250, and (F) TE30+ES100 
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II. Staphylococcus aureus 
A. Identification of S. aureus by staining techniques 
Simple and Gram stains were conducted to identify the morphology of the 
bacterium, shown in Figure 29.  Both stains confirmed the morphology of S. aureus 
as spherical or cocci shaped. The Gram stain indicated the bacterium to be Gram 
positive with evenly sized violet or purple colored cocci dispersed in the smear.  
Figure 29: S. aureus staining. (A) Simple stain at 1000x (B) Gram stain at 1000x. 
B. Determining the optimal inhibitory combined concentration of antibiotics 
and tea polyphenols on bacterial growth 
  This experiment was carried out to test the effect of multiple 
concentrations of antibiotic (tetracycline) and tea polyphenol (EGCG-S) on 
bacterial growth along with certain combined treatments (antibiotic + tea). A CFU 
assay was carried out on the samples to estimate the extent of inhibition 
quantitatively for single and combination treatments. The CFU analysis data to 
determine individual lethal dose (LD50) for both antibiotics and tea polyphenol was 
previously established in the lab. Based on the results, TE30 resulted in 52.86% 
inhibition. Additionally, the tea polyphenol concentration giving 50% inhibition are 
ES25 and ES50. Additionally, multiple combinations were tested to indicate that the 
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TE30+ES50 and TE30+ES75 both gave about 98% inhibition. The combination 
with lower amounts was chosen for previous and continued in this study. 
C. Determining the optimal combination of antibiotics and tea polyphenols to 
inhibit biofilm formation  
  Once the optimal combination concentration for inhibiting the S. aureus 
growth was determined, this experiment was conducted to observe the inhibitory 
effects of single and combination treatments on biofilm production. For consistency 
of the data, this experiment was carried out independently using three different 
assays namely, CV, CFU and Resazurin assay. The results from CV assays are 
indicated in Table 11, 12 and Figure 30 and 31. The data obtained showed that 
single antibiotic or tea polyphenols treatments gave maximum inhibition of 56% 
and 68% respectively. Further testing of certain combinatorial treatments indicated 
that the optimum combination concentration (TE30+ES50) inhibiting the bacterial 
growth only resulted in 56% inhibition. This clearly suggests that this combination 
is not sufficient to inhibit the biofilm formation effectively. Thus, different 
concentration with increasing antibiotic and/or tea polyphenol concentration was 
tested to determine the optimal combination that can provide a maximum inhibition 
of biofilm formation. From the results, it is observed that combination of 
TE15+ES200 effectively inhibits biofilm production by 99.8%. 
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Figure 30: Percentage Inhibition of multiple single treatments on S. aureus biofilm 
formation. 
Table 11: LD50 determination for 
Tetracycline and EGCG-S on S. 
aureus biofilm formation (CV 
assay) 
    Avg % 
Inhibition 
Std. Dev 
PC 0 0 
TE15 51.67219 0.150788 
TE30 56.20483 0.061189 
TE40 34.91202 0.208543 
ES50 34.25954 0.176543 
ES100 38.26435 0.519172 
ES150 68.17209 0.10513 
ES200 56.81638 0.035355 
ES250 22.38272 0.266532 
Table 12: Inhibitory effect of Combined 
Concentration of Tetracycline and 
EGCG-S on S. aureus biofilm formation 
(CV assay)  
Avg % 
Inhibition 
Std. Dev 
PC 0 0 
TE15+ES50 56.37811 0.122008 
TE15+ES100 68.57121 0.042959 
TE15+ES150 90.75166 0.267869 
TE15+ES200 99.87664 0.298839 
TE15+ES250 78.42001 0.700955 
TE30+ES50 55.58929 0.615662 
TE30+ES100 86.41099 0.187446 
TE30+ES150 85.30384 0.136245 
TE30+ES200 78.01258 0.994674 
TE30+ES250 65.46962 0.200309 
TE40+ES50 29.79861 0.396746 
TE40+ES100 41.99171 0.317696 
TE40+ES150 50.88242 0.679975 
TE40+ES200 64.88354 0.034092 
TE40+ES250 71.32567 0.625277 
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Figure 31: Percentage Inhibition of multiple combination treatments on S. aureus 
biofilm formation. 
  Quantitative CFU assay, data shown in Table 13 and Figure 32, and 
fluorescence-dye based spectrophotometric assay (Resaurin assay), data shown in 
Figure 33, 34 and Table 14, was conducted. The results from CFU assay aligns with 
that of the CV assay and Resazurin assay. For instance, optimal combination of 
TE15+ES200 yielded approximately 100% inhibition based on all three assays. A 
minor discrepancy is observed in the LD50 of EGCG-S. According to the Resazurin 
assay, ES100 concentration inhibited 50% of the biofilm formation however, the 
CV and CFU identified ES200 as the LD50. Based on fluorometric data, the 
combination of TE15+ES200 gives the maximum inhibitory effect ~100%. The 
findings from the above mentioned three assays is confirmed using qualitative 
bacterial viability assay. 
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Table 13: CFU analysis of antibiotic and tea concentrations 
on S. aureus biofilm formation 
 Avg Cells/mL Avg % Inhibition Std. Dev 
NC 555000 100 0 
PC 4405000 0 0 
TE15 2265000 52.65283 0.877249 
TE30 1995000 59.3814 0.338269 
TE40 2585000 44.86349 0.557148 
ES50 3180000 30.14217 0.469337 
ES100 2375000 50.05659 0.878114 
ES150 1585000 69.40606 0.808038 
ES200 2005000 59.06513 0.747478 
ES250 3135000 31.31641 0.552823 
TE15+ES50 2195000 57.37431 0.265542 
TE15+ES100 2025000 61.73228 0.806387 
TE15+ES150 945000 89.87512 0.04686 
TE15+ES200 775000 94.35321 0.63359 
TE15+ES250 1575000 73.53187 0.238206 
TE30+ES50 2105000 59.76626 0.244064 
TE30+ES100 1200000 83.07792 1.584951 
TE30+ES150 1140000 84.51239 2.748648 
TE30+ES200 1505000 75.59246 2.513858 
TE30+ES250 1950000 63.74559 0.193787 
TE40+ES50 2980000 35.13217 0.52211 
TE40+ES100 2340000 50.91456 0.814527 
TE40+ES150 2110000 56.46858 0.907961 
TE40+ES200 1700000 66.62904 0.053206 
TE40+ES250 1600000 72.84742 0.09128 
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Figure 32: Percentage Inhibition of S. aureus biofilm formation (CFU assay) 
Figure 33: Fluorescence measurements of treatments on S. aureus biofilm formation 
(Resazurin assay) 
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Table 14: Inhibition of S. aureus biofilm formation by single or 
combination treatments using Resazurin assay  
Avg RLU Std. Dev Avg % Inhibition Std. Dev 
PC 2840.084 21.38998 0 0 
NC 151.93 0 0 0 
TE10 1987.008 31.3121 35.38880784 0.61589 
TE15 1384.909 87.48325 56.59689916 2.753416 
TE30 1212.838 8.650037 62.64529447 0.023234 
TE40 1222.022 12.37649 62.32240869 0.152012 
TE50 1456.916 18.9844 54.05236183 0.322392 
ES25 2390.327 11.00258 21.1818411 0.981019 
ES50 1863.498 2.222437 39.73331728 0.532149 
ES100 1289.616 71.11585 59.95012976 2.202371 
ES150 979.188 54.42177 70.87844869 1.696875 
ES200 946.452 64.1756 72.03241666 2.049001 
ES250 867.6655 29.82647 74.80203127 0.860419 
ES500 603.6315 26.37013 84.09853351 0.808737 
TE15+ES50 1207.869 50.24206 62.82577398 1.489058 
TE15+ES100 854.7395 15.56837 75.25115239 0.734561 
TE15+ES150 358.4505 55.22292 92.73548258 1.889699 
TE15+ES200 241.21 90.28057 96.86831269 3.155213 
TE15+ES250 182.6235 44.56682 98.92515365 1.561113 
TE15+ES500 228.186 47.69435 97.32125692 1.659154 
TE30+ES50 574.8395 59.76679 85.11676335 1.99231 
TE30+ES100 489.1235 29.44039 88.13090754 0.947211 
TE30+ES150 307.5835 49.94932 94.5258727 1.717499 
TE30+ES200 438.8985 23.16977 89.89855985 0.739734 
TE30+ES250 189.0495 45.4507 98.69900352 1.590531 
TE30+ES500 338.783 53.09382 93.42771704 1.819947 
TE40+ES50 532.477 133.2656 86.61814451 4.591527 
TE40+ES100 430.4715 38.65682 90.19733836 1.287287 
TE40+ES150 227.1635 59.22514 97.35878933 2.065438 
TE40+ES200 250.9555 38.05012 96.51823615 1.313531 
TE40+ES250 226.8495 39.32433 97.36720689 1.36479 
TE40+ES500 241.175 71.51678 96.86705708 2.494526 
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Figure 34: Percentage Inhibition of S. aureus biofilm formation (Resazurin assay) 
D. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Finally, another fluorescent dye based microscopic analysis was 
performed to elucidate the optimal combination concentration and confirm the 
findings. This assay qualitatively identifies the viable and nonviable bacterial cells 
using fluorescent dyes exploiting the biochemical changes in the cellular 
membrane’s integrity. The microscopic images are illustrated in Figure 35. The 
control sample had a green fluorescence indicating that the bacterial cells in the 
biofilm were alive.  On treating the biofilm, there is significant increase in red 
fluorescence suggesting that the cells were dead. Based on the CV, CFU and 
Resazurin assay results, different combinations were tested to determine and 
confirm the most consistent one which in this case is TE15+ES200 due to the 
significant number of non-viable cells in the biofilm. 
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 Figure 35: Live and Dead Assay of S. aureus biofilm formation. (A) Control (B) with 
TE15 (C) ES100 (D) ES200 (E) TE15+ES200, and (F) TE15+ES250.  
  Therefore, in conclusion the results from all the four assays described 
above are considered and confirmed to determine the optimal concentrations of 
antibiotic and tea polyphenols to have synergistic anti-biofilm effect on biofilm 
formation process. Thus, the biofilm formation in case S. aureus, generally an 
opportunistic pathogen but occasionally highly infectious, is inhibited by a 
combination of Tetracycline 15 μg/mL and EGCG-S 200 μg/mL. 
A B 
C D 
E F 
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E. Determining optimal combination of antibiotics and tea polyphenols to 
inhibit pre-formed biofilm 
  Once the optimal combination concentration for inhibiting the S. aureus 
growth and biofilm formation was determined this experiment was conducted to 
observe the inhibitory effects of single and combination treatments to reduce. It was 
designed to serve two purpose namely, (i) to establish the LD50 for antibiotic and 
tea polyphenol respectively and (ii) to estimate the extent of inhibitory effect of 
TE30+ES50 combination on pre-formed biofilm. For consistency of the data this 
experiment was carried out independently using two different assays namely, CV 
and CFU assay. The results from CV assays are indicated in Table 15, 16 and 
Figure 36 and 37. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 58%. Further testing of certain 
combinatorial treatments indicated that the inhibitory combination concentration 
(TE30+ES50) for bacterial growth only resulted in 86% inhibition. This clearly 
suggests that the current combination is not sufficient to inhibit the biofilm 
formation effectively. Thus, increasing concentrations of antibiotic and/or tea 
polyphenol were tested to determine the optimal combination that can provide a 
maximum reduction of pre-formed biofilm. From the results, it is observed that 
combination of TE15+ES150 effectively reduced the biofilm to 98%. The optimal 
combination concentration obtained from CV assay was confirmed using the 
quantitative CFU assay. The data is represented in Figure 38 and Table 17. The 
CFU assay supported the CV data indicating that the combination of TE15+ES100 
effectively yields 96% reduction of formed biofilm.  
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 Figure 36: Percentage Inhibition of multiple single treatments on S. aureus 
preformed biofilm. 
Table 15: LD50 determination of 
Tetracycline and EGCG-S on S. 
aureus pre-formed biofilm (CV 
assay) 
  Avg % 
Inhibition 
Std. Dev. 
PC 0 0 
NC 100 0 
TE15 35.47719 1.230827 
TE30 56.25972 3.057907 
TE40 53.7723 1.184593 
ES25 48.80334 1.065883 
ES50 57.99301 1.358908 
ES100 33.70503 2.483312 
ES150 38.14663 0.162236 
ES200 47.14191 0.02999 
Table 16: Inhibitory effect of combined 
concentrations of Tetracycline and 
EGCG-S on S. aureus pre-formed biofilm 
(CV assay)  
Avg % 
Inhibition 
Std. Dev 
NC 100 0 
PC 0 0 
TE15+ES25 63.62437 0.756851 
TE15+ES50 67.85629 1.360047 
TE15+ES100 84.61315 2.172558 
TE15+ES150 83.97604 1.432711 
TE15+ES200 72.25148 2.49696 
TE30+ES25 86.57892 1.648716 
TE30+ES50 83.00482 1.267924 
TE30+ES100 86.54006 2.318996 
TE30+ES150 97.70534 1.47233 
TE30+ES200 72.5959 0.317653 
TE40+ES25 41.82741 2.58435 
TE40+ES50 50.08677 0.481651 
TE40+ES100 62.77488 0.991234 
TE40+ES150 54.98175 0.327996 
TE40+ES200 59.72134 0.877578 
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Figure 37: Percentage Inhibition of multiple combination treatments on S. aureus 
biofilm formation (CV Assay). 
Figure 38: Percentage Inhibition of S. aureus pre-formed biofilm (CFU assay) 
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Table 17: CFU analysis of antibiotic and tea concentrations 
on S. aureus pre-formed biofilm 
 
Avg Cells/mL Avg % Inhibition Std. Dev 
NC 290000 100 0 
PC 3905000 0 0 
TE15 2745000 32.05383 0.824831 
TE30 1815000 57.83827 0.561472 
TE40 2030000 51.86147 0.136838 
ES25 2390000 41.90063 0.192225 
ES50 1775000 58.88266 0.915514 
ES100 2755000 31.77622 0.848181 
ES150 2555000 37.42743 1.974382 
ES200 2345000 43.1251 0.676047 
TE15+ES25 3395000 14.09192 0.379564 
TE15+ES50 2090000 50.1628 1.062126 
TE15+ES100 1275000 72.74651 0.140639 
TE15+ES150 1490000 66.72017 2.016737 
TE15+ES200 1210000 74.50968 0.970358 
TE30+ES25 955000 81.5804 0.571246 
TE30+ES50 725000 87.94886 0.426805 
TE30+ES100 450000 95.55829 0.37359 
TE30+ES150 880000 83.6542 0.592423 
TE30+ES200 1270000 72.89356 0.067333 
TE40+ES50 2380000 42.14522 0.954067 
TE40+ES100 1970000 53.56013 0.78845 
TE40+ES150 1610000 63.48794 0.058645 
TE40+ES200 1900000 55.42083 1.011083 
TE40+ES250 1685000 61.39763 0.312773 
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F. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Fluorescence-based Live and Dead Assay was also conducted to 
qualitatively study the effects of combination treatments on pre-formed biofilm.  
Results for S. aureus treated with multiple combinations are illustrated in Figure 39.  
The control sample had a green fluorescence indicating that the bacterial cells were 
alive.  On treatment, the cells emitting red fluorescence increased suggesting that 
the cells were no longer viable. Based on the microscopic images, the optimal 
combination concentration was determined to be TE30+ES100 which further 
supported the CFU results. 
  In conclusion, the results of the CV assay, CFU viability study and 
bacterial viability assay indicate that EGCG-S at 200ug/mL and 100ug/mL has the 
highest synergistic effect on Tetracycline 15ug/mL and 30ug/mL for inhibiting 
biofilm formation and pre-formed biofilm respectively. These results are indicative 
of the potential synergism of antibiotic and tea polyphenol combination as an anti-
biofilm agent. 
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Figure 39: Live and Dead Assay of S. aureus pre-formed biofilm. (A) Control (B) with 
TE30 (C) TE40 (D) ES50 (E) TE30+ES100, and (F) TE30+ES150 
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III. Bacillus megaterium 
A. Identification of B. megaterium by staining techniques 
Simple and Gram stains were conducted to identify the morphology of the 
bacterium, shown in Figure 40.  Both stains confirmed the morphology of B. 
megaterium as rod or bacilli shaped. The Gram stain indicated the bacterium to be 
Gram positive with evenly sized violet or purple colored bacilli in chains dispersed 
in the smear.  
 
Figure 40: B. megaterium staining. (A) Simple stain at 1000x (B) Gram stain at 1000x. 
B. Determining the optimal inhibitory combined concentration of antibiotics 
and tea polyphenols on bacterial growth 
  This experiment was carried out to test the effect of multiple 
concentrations of antibiotic (erythromycin) and tea polyphenol (EGCG-S) on 
bacterial growth along with certain combined treatments (antibiotic + tea). A CFU 
assay was carried out on the samples to estimate the extent of inhibition 
quantitatively for single and combination treatments. The CFU analysis data to 
determine individual lethal dose (LD50) for both antibiotics and tea polyphenol was 
previously established in the lab. Based on the results, E15 resulted in 47.96% 
inhibition. Additionally, the tea polyphenol concentration giving 52.96 and 55.63% 
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inhibition are ES25 and ES50. Additionally, multiple combinations were tested to 
indicate that the E15+ES25 and E15+ES50 both gave about 93% inhibition. The 
combination with lower amounts was chosen for future experiments. 
C. Determining the optimal combination of antibiotics and tea polyphenols to 
inhibit biofilm formation  
  Once the optimal combination concentration for inhibiting the B. 
megaterium growth was determined, this experiment was conducted to observe the 
inhibitory effects of single and combination treatments on biofilm production. It 
was designed to serve two purposes namely, (i) to establish the LD50 for antibiotic 
and tea polyphenol respectively and (ii) to estimate the extent of inhibition of 
E15+ES25 combination on biofilm production. For consistency of the data, this 
experiment was carried out independently using three different assays namely, CV, 
CFU and Resazurin assay. The results from CV assays are indicated in Table 18, 19 
and Figure 41 and 42. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 58% and 61% respectively. 
Further testing of certain combinatorial treatments indicated that the optimum 
combination concentration (E15+ES25) inhibiting the bacterial growth resulted in 
73% of biofilm inhibition. This clearly suggests that the bactericidal combination 
concentration is not sufficient to inhibit the biofilm formation effectively. Thus, 
different combination concentrations were tested to determine the optimal 
combination that can provide a maximum inhibition of biofilm formation. From the 
results, it is observed that combination of E10+ES50 and E10+ES100 effectively 
inhibits biofilm production to 95 and 97% respectively.   
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Figure 41: Percentage Inhibition of multiple single treatments on B. megaterium 
biofilm formation. 
Table 18: LD50 determination for 
Erythromycin and EGCG-S on B. 
megaterium biofilm formation (CV 
assay) 
 
     Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 51.8649437 1.77145 
E15 58.3777826 0.357466 
E30 30.2689743 0.7847 
ES25 44.3639326 1.191885 
ES50 56.220257 0.98097 
ES100 58.4147338 0.489166 
ES150 62.5437233 1.058434 
ES200 48.2798007 0.568669 
Table 19: Inhibitory effect of Combined 
Concentration of Erythromycin and 
EGCG-S on B. megaterium biofilm 
formation (CV assay)  
Avg % Inhibition Std. Dev 
NC 100 0 
PC 0 0 
E10+ES25 71.03575 0.948949 
E10+ES50 94.91395 0.744979 
E10+ES100 96.98999 0.603049 
E10+ES150 84.02279 0.401909 
E10+ES200 92.68706 0.025604 
E15+ES25 73.14809 0.06758 
E15+ES50 91.73552 0.348116 
E15+ES100 91.41172 0.32005 
E15+ES150 82.67033 0.208648 
E15+ES200 72.89915 0.714328 
E30+ES25 77.472 0.594432 
E30+ES50 87.66055 0.603172 
E30+ES100 91.50755 0.670505 
E30+ES150 79.24183 0.126543 
E30+ES200 21.57646 0.220712 
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Figure 42: Percentage Inhibition of multiple combination treatments on B. 
megaterium biofilm formation. 
  Quantitative CFU assay, data shown in Table 20 and Figure 43, and 
fluorescence-dye based spectrophotometric assay (Resazurin assay), data shown in 
Figure 44, 45 and Table 21, was conducted. The results from CFU assay 
corroborate with that of the CV assay and Resazurin assay. For instance, optimal 
combination of E10+ES100 exhibited maximum inhibition based on all three 
assays. Additionally, the LD50 results are strongly supported by the assays. Based 
on fluorometric data, the combination of E10+ES100 gives the maximum inhibitory 
effect ~97%. Supplementary combinations with high concentration gave similar 
effect but the optimal concentration was confirmed using qualitative bacterial 
viability assay. 
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Table 20: CFU analysis of antibiotic and tea concentrations on B. 
megaterium biofilm formation 
 
Avg Cells/mL Avg % Inhibition Std. Dev 
NC 5550 100 0 
PC 141300 0 0 
E10 66000 55.7032 1.543686 
E15 56000 63.09281 1.696494 
E30 127000 10.59357 0.3932 
ES25 91000 37.22919 1.161665 
ES50 67000 54.60079 0.873501 
ES100 103000 28.29558 0.541585 
ES150 69000 53.3872 0.842778 
ES200 137500 2.73536 0.422314 
E10+ES25 73000 50.29919 0.091765 
E10+ES50 11500 95.54702 0.462124 
E10+ES100 6500 99.24182 0.38572 
E10+ES150 62500 58.1574 0.723748 
E10+ES200 53000 65.0784 0.213851 
E15+ES25 54000 64.14119 1.11156 
E15+ES50 49000 68.16641 1.148395 
E15+ES100 48500 68.13939 1.464225 
E15+ES150 60000 60.0048 0.76195 
E15+ES200 36500 77.23821 0.24763 
E30+ES25 89500 38.13938 0.125544 
E30+ES50 49500 67.86301 1.577464 
E30+ES100 31000 81.23641 0.105036 
E30+ES150 38500 75.6942 0.219642 
E30+ES200 128500 9.187758 1.594917 
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Figure 43: Percentage Inhibition of B. megaterium biofilm formation (CFU assay) 
Figure 44: Fluorescence measurements of treatments on B. megaterium biofilm 
formation (Resazurin assay) 
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Table 21: Inhibition of B. megaterium biofilm formation by single or 
combination treatments using Resazurin assay 
 Avg RLU Std. Dev Avg % Inhibition Std. Dev 
PC 2648.028 68.78664 0 0 
NC 0 0 100 0 
E10 1286.869 69.94417 51.42065 1.379444552 
E15 1599.56 81.01181 39.61364 1.490696921 
E30 2244.875 3.471894 15.19773 2.071758748 
E40 1760.83 12.31568 33.47562 2.193163138 
E50 1315.555 13.84656 50.29587 1.814043211 
ES25 1977.224 41.97244 25.2864 3.525847799 
ES50 1098.02 34.08962 58.5037 2.365290027 
ES100 1702.899 77.35324 35.63214 4.593220086 
ES150 2247.673 4.111119 15.08831 2.36096569 
ES200 1373.328 88.74049 48.16374 2.004664307 
ES250 1972.209 54.88846 25.46951 4.008850913 
ES500 1262.964 32.9137 52.27325 2.482728198 
E10+ES25 556.7885 150.647 79.04028 5.144564854 
E10+ES50 253.9245 28.18881 90.39374 1.314058727 
E10+ES100 80.7085 15.45806 96.95868 0.504754647 
E10+ES150 425.8495 35.16371 83.93006 0.910479336 
E10+ES200 965.913 25.81364 63.49833 1.923013112 
E10+ES250 1349.134 15.38169 49.02664 1.904986193 
E15+ES25 2304.854 26.63247 12.94328 1.255686465 
E15+ES50 998.3975 114.5393 62.22763 5.306652565 
E15+ES100 1500.211 65.68386 43.35922 1.009149888 
E15+ES150 1590.626 54.86229 39.93833 0.511621908 
E15+ES200 299.283 74.51067 88.73063 2.521078482 
E15+ES250 309.9 26.04416 88.30578 0.679754823 
E30+ES25 1331.255 38.09891 49.69088 2.745623539 
E30+ES50 916.58 20.19921 65.38454 0.13638831 
E30+ES100 121.776 81.56901 95.35968 3.200908176 
E30+ES150 172.97 107.8437 93.51868 3.904241917 
E30+ES200 292.461 33.30897 88.96813 0.971308633 
E30+ES250 165.0665 100.0662 93.81343 3.618190605 
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Figure 45: Percentage Inhibition of B. megaterium biofilm formation (Resazurin 
assay) 
D. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Finally, another fluorescent dye based microscopic analysis was 
performed to elucidate the optimal combination concentration and confirm the 
findings. This assay qualitatively identifies the viable and nonviable bacterial cells 
using fluorescent dyes exploiting the biochemical changes in the cellular 
membrane’s integrity. The microscopic images are illustrated in Figure 46. The 
control sample had a green fluorescence indicating that the bacterial cells in the 
biofilm were alive.  On treating the biofilm, there is significant increase in red 
fluorescence suggesting that the cells were dead. Based on the CV, CFU and 
Resazurin assay results, different combinations were tested to determine and 
confirm the most consistent one which in this case is E10+ES100 due to the 
significant number of non-viable cells in the biofilm. 
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Figure 46: Live and Dead Assay of B. megaterium biofilm formation. (A) Control 
(B) with E10 (C) ES50 (D) ES100 (E) E10+ES50, and (F) E10+ES100 
  Therefore, in conclusion the results from all the four assays described 
above are considered and confirmed to determine the optimal concentrations of 
antibiotic and tea polyphenols to have synergistic anti-biofilm effect on biofilm 
formation process. Thus, the biofilm formation in case B. megaterium, an endospore 
forming pathogen, is inhibited by a combination of Erythromycin 10 μg/mL and 
EGCG-S 100 μg/mL. 
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E. Determining optimal combination of antibiotics and tea polyphenols to inhibit 
pre-formed biofilm 
  Once the optimal combination concentration for inhibiting the B. 
megaterium growth and biofilm formation was determined this experiment was 
conducted to observe the inhibitory effects of single and combination treatments to 
reduce. It was designed to serve two purpose namely, (i) to establish the LD50 for 
antibiotic and tea polyphenol respectively and (ii) to estimate the extent of 
inhibitory effect of E15+ES25 combination on pre-formed biofilm. For consistency 
of the data this experiment was carried out independently using two different assays 
namely, CV and CFU assay. The results from CV assays are indicated in Table 22, 
23 and Figure 47 and 48. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 43% and 65% respectively. 
Further testing of certain combinatorial treatments indicated that the inhibitory 
combination concentration (E15+ES25) for bacterial growth only resulted in 58% 
inhibition. This clearly suggests that the bactericidal combination is not sufficient to 
inhibit the biofilm formation effectively. Thus, increasing concentrations of 
antibiotic and/or tea polyphenol were tested to determine the optimal combination 
that can provide a maximum reduction of pre-formed biofilm. From the results, it is 
observed that combination of E15+ES100 effectively reduced the biofilm to 96%. 
The optimal combination concentration obtained from CV assay was confirmed 
using the quantitative CFU assay. The data is represented in Figure 49 and Table 
24. The CFU assay supported the CV data indicating that the combination of 
E15+ES100 effectively yields approximately 94% reduction of pre-formed biofilm. 
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Figure 47: Percentage Inhibition of multiple single treatments on B. megaterium 
preformed biofilm (CV assay) 
 
Table 22: LD50 determination of 
Erythromycin and EGCG-S on 
B. megaterium pre-formed 
biofilm (CV assay)  
Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 43.45349 0.63528 
E15 38.44713 0.114623 
E30 21.86308 1.865676 
ES25 56.95091 1.222401 
ES50 54.16831 0.519942 
ES100 65.12449 0.989962 
ES150 59.50048 0.655473 
ES200 48.00542 0.69501 
Table 23: Inhibitory effect of combined 
concentrations of Erythromycin and 
EGCG-S on B. megaterium pre-formed 
biofilm (CV assay)  
Avg % 
Inhibition 
Std. Dev 
NC 100 0 
PC 0 0 
E10+ES25 46.20899 0.099532 
E10+ES50 79.96575 0.468504 
E10+ES100 64.88606 0.651208 
E10+ES150 53.34436 0.809052 
E10+ES200 43.61968 0.455252 
E15+ES25 57.69789 0.761891 
E15+ES50 49.88302 0.534676 
E15+ES100 96.47339 0.366687 
E15+ES150 47.58744 0.088656 
E15+ES200 36.08717 0.632837 
E30+ES25 43.79973 0.647278 
E30+ES50 46.73668 0.554418 
E30+ES100 19.03937 1.078492 
E30+ES150 29.8308 0.460827 
E30+ES200 43.22144 0.355171 
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Figure 48: Percentage Inhibition of multiple combination treatments on B. 
megaterium pre-formed biofilm (CV Assay) 
Figure 49: Percentage Inhibition of B. megaterium pre-formed biofilm (CFU assay) 
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Table 24: CFU analysis of antibiotic and tea 
concentrations on B. megaterium pre-formed biofilm 
 
Cells/mL Avg % Inhibition Std. Dev. 
PC 7085000 0 0 
E10 3670000 48.25157233 1.52984109 
E15 4130000 41.6842368 0.70576556 
E30 5565000 21.46840371 0.437521 
ES25 3250000 54.11929719 0.27346827 
ES50 3150000 55.52051512 0.57898471 
ES100 2500000 64.69531796 0.56430185 
ES150 2830000 60.03384247 0.67639984 
ES200 3730000 47.34261755 0.32739955 
E10+ES25 3915000 44.74902665 0.19779507 
E10+ES50 2130000 69.9627633 0.78595656 
E10+ES100 2200000 68.87890586 2.08101307 
E10+ES150 3455000 51.22272137 0.36735387 
E10+ES200 3955000 44.19656584 0.56006641 
E15+ES25 3240000 54.24737945 0.66411706 
E15+ES50 3450000 51.33023859 0.73767254 
E15+ES100 602500 91.47672956 0.5799165 
E15+ES150 3730000 47.36268344 0.27276236 
E15+ES200 4310000 39.17140861 0.12423959 
E30+ES25 4005000 43.46251373 0.28744522 
E30+ES50 3800000 46.36577818 0.00649434 
E30+ES100 5595000 21.04402516 0.40914355 
E30+ES150 4695000 33.73525007 0.06014325 
E30+ES200 4075000 42.45223121 0.95382119 
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F. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Fluorescence-based Live and Dead Assay was also conducted to 
qualitatively study the effects of combination treatments on pre-formed biofilm.  
Results for B. megaterium treated with multiple combinations are illustrated in Figure 
50.  The control sample had a green fluorescence indicating that the bacterial cells 
were alive.  On treatment, the cells emitting red fluorescence increased suggesting 
that the cells were no longer viable. Based on the microscopic images, the optimal 
combination concentration was determined to be E15+ES100 which further supported 
the CFU results.  
  In conclusion, the results of the CV assay, CFU viability study and 
bacterial viability assay indicate that EGCG-S at 100ug/mL has the highest 
synergistic effect on Erythromycin 10ug/mL and 15ug/mL for inhibiting biofilm 
formation and pre-formed biofilm respectively. These results are indicative of the 
potential synergism of antibiotic and tea polyphenol combination as an anti-biofilm 
agent. 
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Figure 50: Live and Dead Assay of B. megaterium pre-formed biofilm. (A) Control 
(B) with E10 (C) ES25 (D) ES50 (E) E15+ES100, and (F) E15+ES150 
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IV. Pseudomoas aeruginosa 
A. Identification of P. aeruginosa by staining techniques 
Simple and Gram stains were conducted to identify the morphology of the 
bacterium, shown in Figure 51.  Both stains confirmed the morphology of P. 
aeruginosa as short rod or bacilli shaped. The Gram stain indicated the bacterium to 
be Gram negative with evenly sized pink colored bacilli dispersed in the smear.  
 
Figure 51: P. aeruginosa staining. (A) Simple stain at 1000x (B) Gram stain at 1000x. 
B. Determining the optimal inhibitory combined concentration of antibiotics 
and tea polyphenols on bacterial growth 
  This experiment was carried out to test the effect of multiple 
concentrations of antibiotic (Erythromycin) and tea polyphenol (EGCG-S) on 
bacterial growth along with certain combined treatments (antibiotic + tea). A CFU 
assay was carried out on the samples to estimate the extent of inhibition 
quantitatively for single and combination treatments. The CFU analysis data to 
determine individual lethal dose (LD50) for both antibiotics and tea polyphenol was 
previously established in the lab. Based on the results, E15 resulted in 45.96% 
inhibition. Additionally, the tea polyphenol concentration giving 47.73% inhibition 
is ES50. Additionally, multiple combinations were tested to indicate that the 
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E15+ES25 and E15+ES50 resulted in 96% inhibition of bacterial growth. The 
combination with lower amounts was chosen for the study. 
C. Determining the optimal combination of antibiotics and tea polyphenols to 
inhibit biofilm formation  
  Once the optimal combination concentration for inhibiting the P. 
aeruginosa growth was determined, this experiment was conducted to observe the 
inhibitory effects of single and combination treatments on biofilm production. It 
was designed to serve two purposes namely, (i) to establish the LD50 for antibiotic 
and tea polyphenol respectively and (ii) to estimate the extent of inhibition of 
E15+ES25 combination on biofilm production. For consistency of the data, this 
experiment was carried out independently using three different assays namely, CV, 
CFU and Resazurin assay. The results from CV assays are indicated in Table 25, 26 
and Figure 52 and 53. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 62% and 77% respectively. 
Further testing of certain combinatorial treatments indicated that the optimum 
combination concentration (E15+ES25) inhibiting the bacterial growth only 
resulted in 76% inhibition. This clearly suggests that the bactericidal combination is 
not sufficient to inhibit the biofilm formation effectively. Thus, different 
concentration with increasing antibiotic and/or tea polyphenol concentration was 
tested to determine the optimal combination that can provide a maximum inhibition 
of biofilm formation. From the results, it is observed that combination of E15+ES50 
and E15+ES100 effectively inhibits biofilm production to 93 and 98% respectively. 
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Figure 52: Percentage Inhibition of multiple single treatments on P. aeruginosa 
biofilm formation. 
Table 25: LD50 determination for 
Erythromycin and EGCG-S on P. 
aeruginosa biofilm formation (CV 
assay) 
   Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 62.28654 2.146305 
E15 54.05297 0.917284 
E30 21.1241 0.79058 
ES25 63.84782 0.424097 
ES50 66.21594 1.021993 
ES100 75.72934 1.441309 
ES150 77.01693 1.231173 
ES200 75.57703 1.749461 
Table 26: Inhibitory effect of Combined 
Concentration of Erythromycin and 
EGCG-S on P. aeruginosa biofilm 
formation (CV assay)  
Avg % 
Inhibition 
Std. Dev 
PC 0 0 
E10+ES25 66.49986 0.502982 
E10+ES50 77.14818 0.267189 
E10+ES100 89.80681 0.007221 
E10+ES150 82.94111 1.515224 
E10+ES200 52.84219 0.413814 
E15+ES25 75.64589 1.7931 
E15+ES50 92.67848 0.471916 
E15+ES100 97.69009 0.027392 
E15+ES150 79.51536 1.718527 
E15+ES200 62.08441 0.765535 
E30+ES25 66.76216 1.058387 
E30+ES50 68.72141 0.759691 
E30+ES100 71.94804 1.055498 
E30+ES150 72.55894 1.470238 
E30+ES200 55.28626 0.272703 
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Figure 53: Percentage Inhibition of multiple combination treatments on P.  
aeruginosa biofilm formation. 
  Quantitative CFU assay, data shown in Table 27 and Figure 54, and 
fluorescence-dye based spectrophotometric assay (Resazurin assay), data shown in 
Figure 55, 56 and Table 28, was conducted. The results from CFU assay partly 
corroborate with that of the CV assay and Resazurin assay. For instance, optimal 
combination of E15+ES100 exhibited maximum inhibition based on all three 
assays. Additionally, the LD50 results are strongly supported by the assays. 
Resazurin assay, being the most sensitive but recently employed technique, 
narrowed multiple combinations having high biofilm inhibitory effect. Based on 
fluorometric data, the combination of E15+ES100 gives the maximum inhibitory 
effect ~100%. Supplementary combinations with low concentration of EGCG-S 
gave 91% inhibitory effect and hence, the optimal concentration was confirmed 
using qualitative bacterial viability assay. 
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Table 27: CFU analysis of antibiotic and tea concentrations on 
P. aeruginosa biofilm formation 
 
Avg Cells/mL Avg % Inhibition Std. Dev 
NC 290000 100 0 
PC 3395000 0 0 
E10 1410000 61.13522 0.608981 
E15 1525000 57.46704 0.746053 
E30 2595000 24.65064 0.368253 
ES25 1995000 42.9901 0.906993 
ES50 1735000 51.09703 0.21004 
ES100 955000 75.12079 0.45827 
ES150 1065000 71.71542 0.24141 
ES200 1845000 47.64922 0.450087 
E10+ES25 1360000 65.62696 1.302604 
E10+ES50 1835000 50.20515 0.541765 
E10+ES100 1105000 73.65187 1.490594 
E10+ES150 1550000 59.42118 0.013322 
E10+ES200 1390000 64.65198 1.171604 
E15+ES25 1475000 59.1191 0.440539 
E15+ES50 825000 82.99874 3.408974 
E15+ES100 445000 95.10153 1.391418 
E15+ES150 1435000 63.01968 1.552763 
E15+ES200 2045000 43.38026 1.458769 
E30+ES25 905000 80.09001 1.536481 
E30+ES50 1815000 50.76251 1.833267 
E30+ES100 1005000 76.90182 1.053925 
E30+ES150 2115000 41.13617 1.304824 
E30+ES200 1910000 47.84488 0.279764 
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 Figure 54: Percentage Inhibition of P. aeruginosa biofilm formation (CFU assay) 
Figure 55: Fluorescence measurements of treatments on P. aeruginosa biofilm 
formation (Resazurin assay) 
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Table 28: Inhibition of P. aeruginosa biofilm formation by single or 
combination treatments using Resazurin assay  
Avg RLU Std. Dev Avg % Inhibition Std. Dev 
PC 926.8405 17.73495 0 0 
NC 0 0 100 0 
E10 714.5585 34.9431 22.92579333 2.295328 
E15 468.0025 13.92364 49.48198411 2.468923 
E30 338.2225 24.32942 63.47621381 3.323862 
E40 302.6175 20.31164 67.36455247 1.567019 
E50 374.84 16.13193 59.56647712 0.966841 
ES25 639.2705 11.81646 31.0264841 0.044879 
ES50 247.6535 27.02209 73.30282098 2.404659 
ES100 209.393 14.9242 77.41914292 1.178142 
ES150 186.4265 21.43029 79.90424831 1.927658 
ES200 248.8765 29.91274 73.17382761 2.714073 
ES250 208.2195 23.29139 77.55441776 2.083495 
ES500 244.223 31.37857 73.61272136 3.890458 
E10+ES25 152.928 19.26866 83.47715848 2.395124 
E10+ES50 219.7655 30.99885 76.25240012 3.798979 
E10+ES100 161.042 26.22093 82.59437302 3.16212 
E10+ES150 231.338 16.20406 75.05230947 1.270941 
E10+ES200 193.556 6.255067 79.11921359 0.27533 
E10+ES250 246.044 2.910452 73.44560338 0.822133 
E15+ES25 159.3585 13.74828 82.78892227 1.81268 
E15+ES50 56.905 0.767918 93.85999304 0.034635 
E15+ES100 4.8225 1.775545 99.4777555 0.201563 
E15+ES150 181.363 1.938887 80.4265392 0.583728 
E15+ES200 241.012 6.274866 73.98514894 1.174807 
E15+ES250 194.734 13.20734 78.97199788 1.827353 
E30+ES25 96.5585 15.20067 89.56437077 1.839737 
E30+ES50 60.03 37.35221 93.48340718 4.154752 
E30+ES100 149.381 15.59595 83.86371844 1.991465 
E30+ES150 257.4995 40.87431 72.17020808 4.942588 
E30+ES200 324.8965 22.16002 64.96226298 1.720479 
E30+ES250 235.8375 42.5148 74.50612977 5.074888 
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Figure 56: Percentage Inhibition of P. aeruginosa biofilm formation (Resazurin 
assay) 
D. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Finally, another fluorescent dye based microscopic analysis was 
performed to elucidate the optimal combination concentration and confirm the 
findings. This assay qualitatively identifies the viable and nonviable bacterial cells 
using fluorescent dyes exploiting the biochemical changes in the cellular 
membrane’s integrity. The microscopic images are illustrated in Figure 57. The 
control sample had a green fluorescence indicating that the bacterial cells in the 
biofilm were alive.  On treating the biofilm, there is significant increase in red 
fluorescence suggesting that the cells were dead. Based on the CV, CFU and 
Resazurin assay results, different combinations were tested to determine and 
confirm the most consistent one which in this case is E15+ES100 due to the 
significant number of non-viable cells in the biofilm. 
111 
 
Figure 57: Live and Dead Assay of P. aeruginosa biofilm formation. (A) Control (B) 
with E15 (C) ES25 (D) ES50 (E) E15+ES50, and (F) E15+ES100 
  Therefore, in conclusion the results from all the four assays described 
above are considered and confirmed to determine the optimal concentrations of 
antibiotic and tea polyphenols to have synergistic anti-biofilm effect on biofilm 
formation process. Thus, the biofilm formation in case of P. aeruginosa, an 
opportunistic but chronic infections causing pathogen, is inhibited by a combination 
of Erythromycin 15 μg/mL and EGCG-S 100 μg/mL. 
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E. Determining optimal combination of antibiotics and tea polyphenols to inhibit 
pre-formed biofilm 
  Once the optimal combination concentration for inhibiting the P. 
aeruginosa growth and biofilm formation was determined this experiment was 
conducted to observe the inhibitory effects of single and combination treatments to 
reduce. It was designed to serve two purpose namely, (i) to establish the LD50 for 
antibiotic and tea polyphenol respectively and (ii) to estimate the extent of 
inhibitory effect of E15+ES25 combination on pre-formed biofilm. For consistency 
of the data this experiment was carried out independently using two different assays 
namely, CV and CFU assay. The results from CV assays are indicated in Table 29, 
30 and Figure 58 and 59. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 54% and 51% respectively. 
Further testing of certain combinatorial treatments indicated that the inhibitory 
combination concentration (E15+ES25) for bacterial growth only resulted in 80% 
inhibition. This clearly suggests that the bactericidal combination concentration is 
not sufficient to inhibit the biofilm formation effectively. Thus, increasing 
concentrations of antibiotic and/or tea polyphenol were tested to determine the 
optimal combination that can provide a maximum reduction of pre-formed biofilm. 
From the results, it is observed that combination of E15+ES100 effectively reduced 
the biofilm to 98%. The optimal combination concentration obtained from CV 
assay correlated with that of the quantitative CFU assay indicating that the 
combination of E15+ES100 effectively yields approximately 94% reduction of pre-
formed biofilm. The data is represented in Figure 60 and Table 31. 
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Table 30: Inhibitory effect of combined 
concentrations of Erythromycin and 
EGCG-S on P. aeruginosa pre-formed 
biofilm (CV assay)  
Avg % 
Inhibition 
Std. Dev 
NC 100 0 
PC 0 0 
E10+ES25 47.64627 1.302484 
E10+ES50 50.91594 0.456125 
E10+ES100 71.76734 0.914228 
E10+ES150 36.70546 0.121262 
E10+ES200 57.39287 1.69782 
E15+ES25 80.06201 1.890423 
E15+ES50 94.01488 0.258691 
E15+ES100 98.11019 0.062586 
E15+ES150 83.25789 1.049499 
E15+ES200 68.99056 0.03327 
E30+ES25 72.80123 1.443929 
E30+ES50 74.40656 1.165508 
E30+ES100 77.04347 1.351363 
E30+ES150 77.53959 1.680007 
E30+ES200 63.42518 0.554669 
Figure 58: Percentage inhibition of single treatments on P. aeruginosa pre-formed 
biofilm (CV assay) 
Table 29: LD50 determination of 
Erythromycin and EGCG-S on 
P.aeruginosa pre-formed biofilm 
(CV assay) 
   Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 31.40712 2.76113 
E15 53.38223 1.865857 
E30 19.87889 2.551573 
ES25 51.27183 0.007337 
ES50 49.50856 1.278465 
ES100 34.13812 3.34437 
ES150 25.42131 1.332101 
ES200 37.3187 0.597962 
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Figure 59: Percentage Inhibition of multiple combination treatments on P. aeruginosa 
pre-formed biofilm (CV Assay) 
Figure 60: Percentage Inhibition of P. aeruginosa pre-formed biofilm (CFU assay) 
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Table 31: CFU analysis of antibiotic and tea concentrations on 
P. aeruginosa pre-formed biofilm 
 
Cells/mL Avg % Inhibition Std. Dev 
NC 290000 100 0 
PC 3395000 0 0 
E10 2560000 25.72645 0.35666 
E15 1530000 57.24667 1.44096 
E30 2595000 24.65064 0.368253 
ES25 1990000 43.08316 1.541888 
ES50 1730000 51.3174 0.904947 
ES100 2445000 29.22489 0.061375 
ES150 2355000 32.17313 1.80853 
ES200 1845000 47.64922 0.450087 
E10+ES25 2110000 41.40674 0.325651 
E10+ES50 1835000 50.20515 0.541765 
E10+ES100 1105000 73.65187 1.490594 
E10+ES150 1950000 46.42139 1.733352 
E10+ES200 1390000 64.65198 1.171604 
E15+ES25 925000 76.14597 1.524839 
E15+ES50 885000 80.74 1.449147 
E15+ES100 1045000 75.87974 2.907196 
E15+ES150 445000 95.10153 1.391418 
E15+ES200 410000 96.22357 1.314446 
E30+ES25 905000 80.09001 1.536481 
E30+ES50 1815000 50.76251 1.833267 
E30+ES100 1005000 76.90182 1.053925 
E30+ES150 2115000 41.13617 1.304824 
E30+ES200 1910000 47.84488 0.279764 
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F. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Fluorescence-based Live and Dead Assay was also conducted to 
qualitatively study the effects of combination treatments on pre-formed biofilm.  
Results for P. aeruginosa treated with multiple combinations are illustrated in 
Figure 61.  The control sample had a green fluorescence indicating that the bacterial 
cells were alive.  On treatment, the cells emitting red fluorescence increased 
suggesting that the cells were no longer viable. Based on the microscopic images, 
the optimal combination concentration was determined to be E15+ES150 which 
further supported the CFU results.  
  In conclusion, the results of the CV assay, CFU viability study and 
bacterial viability assay indicate that EGCG-S at 100 ug/mL and 150ug/mL has 
the highest synergistic effect on Erythromycin 15 ug/mL for inhibiting biofilm 
formation and pre-formed biofilm respectively. These results are indicative of the 
potential synergism of antibiotic and tea polyphenol combination as an anti-biofilm 
agent. 
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Figure 61: Live and Dead Assay of P. aeruginosa pre-formed biofilm. (A) Control (B) 
with E15 (C) ES25 (D) ES50 (E) E15+ES150, and (F) E15+ES200 
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V. Mycobacterium smegmatis 
A. Identification of M. smegmatis by staining techniques 
Simple and Acid Fast stains were conducted to identify the morphology of 
the bacterium, shown in Figure 62.  Both stains confirmed the morphology of M. 
semgmatis as long slender rods or bacilli shaped. The special stain indicated the 
bacterium to be Acid-fast positive with evenly sized pink colored rods in the smear.  
 
Figure 62: M. smegmatis staining. (A) Simple stain at 1000x (B) Acid-Fast stain at 1000x. 
B. Determining the optimal inhibitory combined concentration of antibiotics 
and tea polyphenols on bacterial growth 
  This experiment was carried out to test the effect of multiple 
concentrations of antibiotic (Erythromycin) and tea polyphenol (EGCG-S) on 
bacterial growth along with certain combined treatments (antibiotic + tea). A CFU 
assay was carried out on the samples to estimate the extent of inhibition 
quantitatively for single and combination treatments. The CFU analysis data to 
determine individual lethal dose (LD50) for both antibiotics and tea polyphenol 
was previously established in the lab. Based on the results, E15 resulted in 
31.29% inhibition. Additionally, the tea polyphenol concentration giving 
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approximately 50% inhibition are ES25 and ES50. Additionally, multiple 
combinations were tested to indicate that the E15+ES25 and E15+ES50 resulted 
in 90% and 93% inhibition of bacterial growth. The combination with lower 
amounts was chosen for the study. 
C. Determining the optimal combination of antibiotics and tea polyphenols to 
inhibit biofilm formation  
  Once the optimal combination concentration for inhibiting the M. 
smegmatis growth was determined, this experiment was conducted to observe the 
inhibitory effects of single and combination treatments on biofilm production. It 
was designed to serve two purposes namely, (i) to establish the LD50 for antibiotic 
and tea polyphenol respectively and (ii) to estimate the extent of inhibition of 
E15+ES25 combination on biofilm production. For consistency of the data, this 
experiment was carried out independently using three different assays namely, CV, 
CFU and Resazurin assay. The results from CV assays are indicated in Table 32, 33 
and Figure 63 and 64. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 54% and 50% respectively. 
Further testing of certain combinatorial treatments indicated that the optimum 
combination concentration (E15+ES25) inhibiting the bacterial growth only 
resulted in 73% inhibition. Different concentration with increasing antibiotic and/or 
tea polyphenol concentration was tested to determine the optimal combination that 
can provide a maximum inhibition of biofilm formation. From the results, it is 
observed that combination of E15+ES150 effectively inhibits biofilm production to 
93%.  
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Figure 63: Percentage Inhibition of multiple single treatments on M. smegmatis 
biofilm formation. 
Table 32: LD50 determination for 
Erythromycin and EGCG-S on M. 
smegmatis biofilm formation (CV 
assay)  
Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 29.1379288 1.123806 
E15 54.7048218 2.53893 
E30 51.1381658 2.087717 
ES25 28.4212133 1.187719 
ES50 28.3966316 0.669106 
ES100 45.1843776 2.120665 
ES150 50.2861468 1.921963 
ES200 12.9677811 1.552229 
Table 33: Inhibitory effect of Combined 
Concentration of Erythromycin and 
EGCG-S on M. smegmatis biofilm 
formation (CV assay)  
Avg % 
Inhibition 
Std. Dev 
NC 100 0 
PC 0 0 
E10+ES25 68.56504 0.60967 
E10+ES50 68.1027 0.062245 
E10+ES100 47.04773 0.134535 
E10+ES150 46.0572 0.17028 
E10+ES200 52.45825 1.303771 
E15+ES25 72.96824 0.018098 
E15+ES50 72.40687 0.182256 
E15+ES100 88.76417 1.36464 
E15+ES150 93.35594 1.415237 
E15+ES200 83.57688 0.238009 
E30+ES25 63.34757 0.999121 
E30+ES50 53.87649 1.168558 
E30+ES100 63.36 1.803208 
E30+ES150 51.9652 0.27854 
E30+ES200 37.14543 0.815407 
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Figure 64: Percentage Inhibition of multiple combination treatments on M. 
smegmatis biofilm formation. 
  Quantitative CFU assay, data shown in Table 34 and Figure 65, and 
fluorescence-dye based spectrophotometric assay (Resazurin assay), data shown in 
Figure 66, 67 and Table 35, was conducted. The results from CFU assay partly 
corroborate with that of the CV assay and Resazurin assay. For instance, optimal 
combination of E15+ES100 exhibited maximum inhibition based on all three 
assays. Additionally, the LD50 results are strongly supported by the assays. 
Resazurin assay, being the most sensitive but recently employed technique, 
narrowed multiple combinations having high biofilm inhibitory effect. Based on 
fluorometric data, the combination of E15+ES100 gives the maximum inhibitory 
effect ~100%. Supplementary combinations with low concentration of EGCG-S 
gave 91% inhibitory effect and hence, the optimal concentration was confirmed 
using qualitative bacterial viability assay. 
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Table 34: CFU analysis of antibiotic and tea concentrations on 
M. smegmatis biofilm formation 
 
Cells/mL Avg % Inhibition Std. Dev 
NC 5550 100 0 
PC 160000 0 0 
E10 118000 27.15857 1.416518 
E15 83000 49.91421 2.445148 
E30 70000 58.29638 1.024475 
ES25 116000 28.49995 0.480482 
ES50 112000 31.16026 3.357738 
ES100 77500 53.33356 3.339041 
ES150 92000 43.99027 1.507628 
ES200 137500 14.64146 3.006353 
E10+ES25 63000 62.81158 0.330016 
E10+ES50 61000 64.13051 1.310271 
E10+ES100 81500 50.87534 2.034408 
E10+ES150 75000 55.1001 2.699189 
E10+ES200 83000 49.80194 2.138577 
E15+ES25 59000 65.44943 2.290527 
E15+ES50 44000 75.19544 3.683599 
E15+ES100 48500 72.33451 5.832563 
E15+ES150 13500 94.84315 0.389965 
E15+ES200 37500 79.37529 2.51489 
E30+ES25 64500 61.85045 0.740756 
E30+ES50 80000 51.74665 2.043311 
E30+ES100 63000 62.69931 4.253708 
E30+ES150 78500 52.64041 5.204286 
E30+ES200 103500 36.50186 3.24793 
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Figure 65: Percentage Inhibition of M. smegmatis biofilm formation (CFU assay) 
Figure 66: Fluorescence measurements of treatments on M. smegmatis biofilm 
formation (Resazurin assay) 
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Table 35: Inhibition of M. smegmatis biofilm formation by single or 
combination treatments using Resazurin assay  
Avg RLU Std. Dev Avg % Inhibition Std. Dev 
PC 406.8515 26.10568 0 0 
NC 0 0 100 0 
E10 328.9635 10.75297 19.06226 2.550407 
E15 181.863 5.984952 55.25499 1.400028 
E30 184.5455 13.91798 54.65698 0.51146 
E40 146.494 2.596496 63.93949 1.675634 
E50 171.4805 14.69156 57.88097 0.908464 
ES25 228.4295 23.57423 43.92479 2.196236 
ES50 142.9435 6.817216 64.84732 0.579973 
ES100 151.9325 8.955507 62.65025 0.195377 
ES150 175.277 0.130108 56.82878 2.802066 
ES200 176.5665 10.57902 56.5958 0.184818 
ES250 188.1795 10.38669 53.73404 0.415717 
ES500 213.1165 21.60565 47.68078 1.953382 
E10+ES25 182.1495 3.696047 55.10793 3.788956 
E10+ES50 254.8245 8.920152 37.30799 1.830157 
E10+ES100 151.381 0.46669 62.71901 2.277431 
E10+ES150 169.9675 4.553061 58.10155 3.807516 
E10+ES200 166.85 1.029547 58.89722 2.890417 
E10+ES250 212.416 6.979144 47.73774 1.638011 
E15+ES25 202.836 13.99364 50.15269 0.241038 
E15+ES50 186.8195 9.979398 54.06578 0.494539 
E15+ES100 34.5855 5.100361 91.44139 1.802781 
E15+ES150 3.4605 7.907575 99.08521 2.0023 
E15+ES200 48.9755 7.976872 87.87445 2.738672 
E15+ES250 91.74 10.52458 77.48788 1.142342 
E30+ES25 227.183 7.966265 44.10847 1.628259 
E30+ES50 241.3905 10.57054 40.62978 1.211365 
E30+ES100 235.373 16.21254 42.15646 0.273342 
E30+ES150 210.942 16.40205 48.17524 0.706116 
E30+ES200 220.9975 7.266936 45.62641 1.702748 
E30+ES250 233.1735 19.89162 42.72726 1.214248 
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Figure 67: Percentage Inhibition of M. smegmatis biofilm formation (Resazurin 
assay) 
D. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Finally, another fluorescent dye based microscopic analysis was 
performed to elucidate the optimal combination concentration and confirm the 
findings. This assay qualitatively identifies the viable and nonviable bacterial cells 
using fluorescent dyes exploiting the biochemical changes in the cellular 
membrane’s integrity. The microscopic images are illustrated in Figure 68. The 
control sample had a green fluorescence indicating that the bacterial cells in the 
biofilm were alive.  On treating the biofilm, there is significant increase in red 
fluorescence suggesting that the cells were dead. Based on the CV, CFU and 
Resazurin assay results, different combinations were tested to determine and 
confirm the most consistent one which in this case is E15+ES150 due to the 
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significant number of non-viable cells in the biofilm. The number of dead cells 
were also high in E15+ES100 however, based on the other assays it only inhibited 
the biofilm formation with an average of approximately 82%. Thus, the 
combination with higher concentration of EGCG-S was chosen to obtain desired 
inhibition.   
  Therefore, in conclusion the results from all the four assays described 
above are considered and confirmed to determine the optimal concentrations of 
antibiotic and tea polyphenols to have synergistic anti-biofilm effect on biofilm 
formation process. Thus, the biofilm formation in case of M. smegmatis, a non-
pathogenic model bacteria from the genus Mycobacterium, is inhibited by a 
combination of Erythromycin 15 μg/mL and EGCG-S 150 μg/mL. 
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 Figure 68: Live and Dead Assay of M. smegmatis biofilm formation. (A) Control (B) 
with E15 (C) ES100 (D) ES150 (E) E15+ES100, and (F) E15+ES150  
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E. Determining optimal combination of antibiotics and tea polyphenols to inhibit 
pre-formed biofilm 
  Once the optimal combination concentration for inhibiting the M. 
smegmatis growth and biofilm formation was determined this experiment was 
conducted to observe the inhibitory effects of single and combination treatments to 
reduce. It was designed to serve two purpose namely, (i) to establish the LD50 for 
antibiotic and tea polyphenol respectively and (ii) to estimate the extent of 
inhibitory effect of E15+ES25 combination on pre-formed biofilm. For consistency 
of the data this experiment was carried out independently using two different assays 
namely, CV and CFU assay. The results from CV assays are indicated in Table 36, 
37 and Figure 69 and 70. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 50% and 79% respectively. 
Further testing of certain combinatorial treatments indicated that the inhibitory 
combination concentration (E15+ES25) for bacterial growth only resulted in 62% 
inhibition. This clearly suggests that the bactericidal combination concentration is 
not sufficient to inhibit the biofilm formation effectively. Thus, increasing 
concentrations of antibiotic and/or tea polyphenol were tested to determine the 
optimal combination that can provide a maximum reduction of pre-formed biofilm. 
From the results, it is observed that combination of E30+ES50 effectively reduced 
the biofilm to 98%. The optimal combination concentration obtained from CV 
assay correlated with that of the quantitative CFU assay indicating that the 
combination of E15+ES100 effectively yields approximately 91% reduction of pre-
formed biofilm. The data is represented in Figure 71 and Table 38. 
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Table 37: Inhibitory effect of combined 
concentrations of Erythromycin and EGCG-
S on M. smegmatis pre-formed biofilm (CV 
assay)  
Avg % Inhibition Std. Dev 
NC 100 0 
PC 0 0 
E10+ES25 65.64561 1.9868 
E10+ES50 74.20981 1.043277 
E10+ES100 75.95964 0.448981 
E10+ES150 69.57849 0.621163 
E10+ES200 59.72031 1.345608 
E15+ES25 62.00623 0.05632 
E15+ES50 55.78413 0.726877 
E15+ES100 59.27364 0.839189 
E15+ES150 62.2892 1.347185 
E15+ES200 60.05821 0.570847 
E30+ES25 65.29486 1.292838 
E30+ES50 83.68555 1.025921 
E30+ES100 91.2304 0.625217 
E30+ES150 75.79594 1.348303 
E30+ES200 57.70916 1.319814 
Figure 69: Percentage inhibition of single treatments on M. smegmatis pre-formed 
biofilm (CV assay) 
Table 36: LD50 determination 
of Erythromycin and EGCG-S 
on M. smegmatis pre-formed 
biofilm (CV assay) 
  Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 44.99588 1.88908 
E15 50.38881 0.855642 
E30 49.41666 1.362875 
ES25 61.05094 0.886433 
ES50 57.67385 1.194421 
ES100 79.56197 0.991954 
ES150 61.8263 1.179981 
ES200 58.27502 1.750101 
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Figure 70: Percentage Inhibition of multiple combination treatments on M. 
smegmatis pre-formed biofilm (CV Assay) 
Figure 71: Percentage Inhibition of M. smegmatis pre-formed biofilm (CFU assay) 
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Table 38: CFU analysis of antibiotic and tea concentrations 
on M. smegmatis pre-formed biofilm  
Avg % Inhibition Std. Dev. 
PC 0 0 
E10 41.75112309 1.29477414 
E15 48.09004692 0.92022003 
E30 54.11929719 0.27346827 
ES25 64.69531796 0.56430185 
ES50 55.52051512 0.57898471 
ES100 76.3618848 2.21188818 
ES150 60.03384247 0.67639984 
ES200 59.3332335 0.52364162 
E10+ES25 59.63571928 2.1912757 
E10+ES50 76.61904762 2.76108362 
E10+ES100 74.87421384 2.17913411 
E10+ES150 69.9627633 0.78595656 
E10+ES200 51.22272137 0.36735387 
E15+ES25 65.51423233 0.79544399 
E15+ES50 51.33023859 0.73767254 
E15+ES100 54.24737945 0.66411706 
E15+ES150 61.50863532 1.2186774 
E15+ES200 58.84196865 2.55255877 
E30+ES25 61.85225117 0.94224432 
E30+ES50 83.68533493 2.48818008 
E30+ES100 93.79534791 2.27979641 
E30+ES150 73.21014276 1.29237406 
E30+ES200 56.59818309 0.00790616 
   
F. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Fluorescence-based Live and Dead Assay was also conducted to 
qualitatively study the effects of combination treatments on pre-formed biofilm.  
Results for M. smegmatis treated with multiple combinations are illustrated in 
Figure 72.  The control sample had a green fluorescence indicating that the bacterial 
cells were alive.  On treatment, the cells emitting red fluorescence increased 
suggesting that the cells were no longer viable. Based on the microscopic images, 
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the optimal combination concentration was determined to be E30+ES50 which 
further supported the CFU results.  
  In conclusion, the results of the CV assay, CFU viability study and 
bacterial viability assay indicate that EGCG-S at 150 ug/mL and 50 ug/mL has the 
highest synergistic effect on Erythromycin 15 ug/mL and 30 ug/mL for inhibiting 
biofilm formation and pre-formed biofilm respectively. These results are indicative 
of the potential synergism of antibiotic and tea polyphenol combination as an anti-
biofilm agent. 
Figure 72: Live and Dead Assay of M. smegmatis pre-formed biofilm. (A) Control (B) 
with E15 (C) ES50 and (D) E30+ES50. 
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VI. Escherichia coli 
A. Identification of E. coli by staining techniques 
Simple and Acid Fast stains were conducted to identify the morphology of 
the bacterium, shown in Figure 73.  Both stains confirmed the morphology of E. 
coli as small rods or coccobacilli shaped. The Gram stain indicated the bacterium to 
be Gram positive with evenly sized pink colored rods in the smear.  
 
Figure 73: E. coli staining. (A) Simple stain at 1000x (B) Gram stain at 1000x. 
B. Determining the optimal inhibitory combined concentration of antibiotics 
and tea polyphenols on bacterial growth 
  This experiment was carried out to test the effect of multiple 
concentrations of antibiotic (Erythromycin) and tea polyphenol (EGCG-S) on 
bacterial growth along with certain combined treatments (antibiotic + tea). A CFU 
assay was carried out on the samples to estimate the extent of inhibition 
quantitatively for single and combination treatments. The CFU analysis data to 
determine individual lethal dose (LD50) for both antibiotics and tea polyphenol 
was previously established in the lab. Based on the results, E15 resulted in 
52.27% inhibition. Additionally, the tea polyphenol concentration giving 
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approximately 50% inhibition are ES100. Multiple combinations were also tested 
to indicate that the E15+ES25 and E15+ES50 resulted in 98% inhibition of 
bacterial growth. The combination with lower amounts was chosen for the study. 
C. Determining the optimal combination of antibiotics and tea polyphenols to 
inhibit biofilm formation  
  Once the optimal combination concentration for inhibiting the E. coli 
growth was determined, this experiment was conducted to observe the inhibitory 
effects of single and combination treatments on biofilm production. It was designed 
to serve two purposes namely, (i) to establish the LD50 for antibiotic and tea 
polyphenol respectively and (ii) to estimate the extent of inhibition of E15+ES25 
combination on biofilm production. For consistency of the data, this experiment 
was carried out independently using three different assays namely, CV, CFU and 
Resazurin assay. The results from CV assays are indicated in Table 39, 40 and 
Figure 74 and 75. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 44% and 53% respectively. 
Further testing of certain combinatorial treatments indicated that the optimum 
combination concentration (E15+ES25) inhibiting the bacterial growth only 
resulted in 85% inhibition. Different concentration with increasing antibiotic and/or 
tea polyphenol concentration was tested to determine the optimal combination that 
can provide a maximum inhibition of biofilm formation. From the results, it is 
observed that combination of E10+ES150 and E10+ES200 effectively inhibits 
biofilm production to 97%.  
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Table 40: Inhibitory effect of Combined 
Concentration of Erythromycin and 
EGCG-S on E. coli biofilm formation 
(CV assay)  
Avg % 
Inhibition 
Std. Dev 
NC 100 0 
PC 0 0 
E10+ES25 63.04878027 1.220359 
E10+ES50 85.99870748 0.780081 
E10+ES100 89.6321153 0.215355 
E10+ES150 97.25038314 0.83034 
E10+ES200 96.79504643 1.436987 
E15+ES25 85.30768418 0.757381 
E15+ES50 74.75379745 0.74079 
E15+ES100 89.96501079 0.107561 
E15+ES150 82.45496287 0.016166 
E15+ES200 59.77081501 0.605141 
E30+ES25 77.04218206 0.015848 
E30+ES50 87.1102943 2.765373 
E30+ES100 72.79986847 0.445858 
E30+ES150 80.14368616 1.466412 
E30+ES200 52.02698567 0.398251 
Figure 74: Percentage Inhibition of multiple single treatments on E. coli biofilm 
formation 
Table 39: LD50 determination for 
Erythromycin and EGCG-S on E. 
coli biofilm formation (CV assay) 
  Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 25.0863029 1.138426 
E15 44.9540628 0.67479 
E30 36.9385586 0.249511 
ES25 36.2755428 0.192209 
ES50 53.11178 2.00498 
ES100 34.4262784 0.989071 
ES150 43.9012664 1.582883 
ES200 50.131067 2.210385 
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Figure 75: Percentage Inhibition of multiple combination treatments on E. coli 
biofilm formation 
  Quantitative CFU assay, data shown in Table 41 and Figure 76, and 
fluorescence-dye based spectrophotometric assay (Resazurin assay), data shown in 
Figure 77, 78 and Table 42, was conducted. The results from CFU assay partly 
corroborate with that of the CV assay and Resazurin assay. For instance, optimal 
combination of E10+ES150 exhibited maximum inhibition based on all three 
assays. Additionally, the LD50 results are strongly supported by the assays. 
Resazurin assay, being the most sensitive but recently employed technique, 
narrowed multiple combinations having high biofilm inhibitory effect. Based on 
fluorometric data, the combination of E10+ES150 and E10+ES200 gives the 
maximum inhibitory effect ~94%. Hence, the optimal concentration was confirmed 
using qualitative bacterial viability assay. 
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Table 41: CFU analysis of antibiotic and tea 
concentrations on E. coli biofilm formation 
 
Cells/mL Avg % Inhibition Std. Dev 
NC 55500 100 0 
PC 1810000 0 0 
E10 1335000 27.0132737 1.59135 
E15 1100000 40.52170236 1.441844 
E30 1125000 38.98612425 1.495058 
ES25 1095000 40.700883 1.365824 
ES50 872000 53.38938104 1.941042 
ES100 1100000 40.39985952 1.791536 
ES150 1085000 41.30292996 0.514401 
ES200 825000 56.10325105 1.011065 
E10+ES25 680000 64.40648204 0.017738 
E10+ES50 380000 81.49314813 0.306614 
E10+ES100 300000 86.06583814 0.03801 
E10+ES150 90000 98.03868868 0.134302 
E10+ES200 110000 96.92597689 0.856491 
E15+ES25 185000 92.65431037 0.937579 
E15+ES50 165000 93.76702216 0.21539 
E15+ES100 240000 89.49535564 0.296478 
E15+ES150 360000 82.66678134 0.587887 
E15+ES200 835000 55.50120409 1.862488 
E30+ES25 500000 74.63411313 0.823549 
E30+ES50 345000 83.50893036 0.248332 
E30+ES100 485000 75.50672286 0.35476 
E30+ES150 335000 84.08051661 0.29141 
E30+ES200 825000 56.13371176 0.20272 
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Figure 76: Percentage Inhibition of E. coli biofilm formation (CFU assay) 
Figure 77: Fluorescence measurements of treatments on E. coli biofilm formation 
(Resazurin assay) 
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Table 42: Inhibition of E. coli biofilm formation by single or 
combination treatments using Resazurin assay  
Avg RLU Std. Dev Avg % Inhibition Std. Dev 
PC 2648.028 68.78664 0 0 
NC 0 0 100 0 
E10 1486.869 69.94417 43.86531 1.183183 
E15 1549.56 10.30113 41.46779 1.131454 
E30 1594.875 74.18257 39.78728 1.237308 
E40 1760.83 12.31568 33.47562 2.193163 
E50 1315.555 13.84656 50.29587 1.814043 
ES25 1577.224 41.97244 40.39708 3.133324 
ES50 1098.02 34.08962 58.5037 2.36529 
ES100 1702.899 77.35324 35.63214 4.59322 
ES150 1547.673 4.111119 41.532 1.67405 
ES200 1103.328 46.31408 58.34263 0.666888 
ES250 972.209 86.5329 63.31561 2.314891 
ES500 1262.964 32.9137 52.27325 2.482728 
E10+ES25 556.7885 150.647 79.04028 5.144565 
E10+ES50 503.9245 42.52187 80.98426 1.11183 
E10+ES100 380.7085 15.45806 85.62567 0.210362 
E10+ES150 175.8495 35.54696 93.33954 1.51541 
E10+ES200 65.913 25.81364 97.49736 1.039835 
E10+ES250 349.1335 15.38169 86.80334 0.923677 
E15+ES25 304.854 26.63247 88.49669 0.706931 
E15+ES50 1098.398 26.88208 58.51935 0.062351 
E15+ES100 600.2105 75.7375 77.28886 3.450105 
E15+ES150 390.6255 54.86229 85.27037 1.689192 
E15+ES200 699.283 66.91069 73.55056 3.213878 
E15+ES250 309.9 26.04416 88.30578 0.679755 
E30+ES25 1131.255 38.09891 57.24622 2.549362 
E30+ES50 916.58 20.19921 65.38454 0.136388 
E30+ES100 471.776 10.85833 82.17253 0.87315 
E30+ES150 622.97 37.13301 76.48447 0.791437 
E30+ES200 292.461 33.30897 88.96813 0.971309 
E30+ES250 1165.067 100.0662 56.03673 2.636882 
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Figure 78: Percentage Inhibition of E. coli biofilm formation (Resazurin assay) 
D. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Finally, another fluorescent dye based microscopic analysis was 
performed to elucidate the optimal combination concentration and confirm the 
findings. This assay qualitatively identifies the viable and nonviable bacterial cells 
using fluorescent dyes exploiting the biochemical changes in the cellular 
membrane’s integrity. The microscopic images are illustrated in Figure 79. The 
control sample had a green fluorescence indicating that the bacterial cells in the 
biofilm were alive.  On treating the biofilm, there is significant increase in red 
fluorescence suggesting that the cells were dead. Based on the CV, CFU and 
Resazurin assay results, different combinations were tested to determine and 
confirm the most consistent one which in this case is E15+ES200 due to the 
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significant number of non-viable cells in the biofilm. The number of dead cells 
were remarkably high in E15+ES150 combination treatment and thus, the higher 
EGCG-S concentration in the combination was chosen to obtain desired inhibition.   
  Therefore, in conclusion the results from all the four assays described 
above are considered and confirmed to determine the optimal concentrations of 
antibiotic and tea polyphenols to have synergistic anti-biofilm effect on biofilm 
formation process. Thus, the biofilm formation in case of E. coli, a potential 
pathogenic bacterium causing gastro-intestinal infections, is inhibited by a 
combination of Erythromycin 10 μg/mL and EGCG-S 200 μg/mL. 
 
 
142 
 
Figure 79: Live and Dead Assay of E. coli biofilm formation. (A) Control (B) with E10 
(C) E15 (D) ES50 (E) E10+ES150 and (F) E10+ES200 
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E. Determining optimal combination of antibiotics and tea polyphenols to inhibit 
pre-formed biofilm 
  Once the optimal combination concentration for inhibiting the E. coli 
growth and biofilm formation was determined this experiment was conducted to 
observe the inhibitory effects of single and combination treatments to reduce. It was 
designed to serve two purpose namely, (i) to establish the LD50 for antibiotic and 
tea polyphenol respectively and (ii) to estimate the extent of inhibitory effect of 
E15+ES25 combination on pre-formed biofilm. For consistency of the data this 
experiment was carried out independently using two different assays namely, CV 
and CFU assay. The results from CV assays are indicated in Table 43, 44 and 
Figure 80 and 81. The data obtained showed that single antibiotic or tea 
polyphenols treatments gave maximum inhibition of 52% and 51% respectively. 
Further testing of certain combinatorial treatments indicated that the inhibitory 
combination concentration (E15+ES25) for bacterial growth only resulted in 30% 
inhibition. This clearly suggests that the bactericidal combination concentration is 
not sufficient to inhibit the biofilm formation effectively. Thus, increasing 
concentrations of antibiotic and/or tea polyphenol were tested to determine the 
optimal combination that can provide a maximum reduction of pre-formed biofilm. 
From the results, it is observed that combination of E15+ES150 effectively reduced 
the biofilm to 91%. The optimal combination concentration obtained from CV 
assay correlated with that of the quantitative CFU assay indicating that the 
combination of E15+ES150 effectively yields approximately 91% reduction of pre-
formed biofilm. The data is represented in Figure 82 and Table 45. 
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Table 44: Inhibitory effect of combined 
concentrations of Erythromycin and 
EGCG-S on E. coli pre-formed biofilm 
(CV assay)  
Avg % 
Inhibition 
Std. Dev 
NC 100 0 
PC 0 0 
E10+ES25 37.95543082 0.509132 
E10+ES50 34.59918936 0.350788 
E10+ES100 48.12966068 0.216066 
E10+ES150 57.5497113 0.825989 
E10+ES200 43.91097667 1.218006 
E15+ES25 30.34102943 1.779512 
E15+ES50 74.1162042 1.114932 
E15+ES100 84.98500545 1.031358 
E15+ES150 91.05247855 0.975642 
E15+ES200 87.88246733 2.832711 
E30+ES25 70.03147043 0.009472 
E30+ES50 81.40030005 0.145084 
E30+ES100 88.73301196 0.415362 
E30+ES150 56.8826785 0.017606 
E30+ES200 39.39500192 0.925665 
Figure 80: Percentage inhibition of single treatments on E. coli pre-formed biofilm 
(CV assay) 
Table 43: LD50 determination of 
Erythromycin and EGCG-S on E. 
coli pre-formed biofilm (CV 
assay)  
Avg % 
Inhibition 
Std. Dev 
PC 0 0 
NC 100 0 
E10 44.4137628 0.601342 
E15 52.676838 1.76146 
E30 32.1228434 1.166915 
ES25 40.7070445 2.106453 
ES50 19.9254921 0.969012 
ES100 51.5317604 2.691749 
ES150 49.104976 0.623462 
ES200 34.398264 1.685965 
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Figure 81: Percentage Inhibition of multiple combination treatments on E. coli 
pre-formed biofilm (CV Assay) 
Figure 82: Percentage Inhibition of E. coli pre-formed biofilm (CFU assay) 
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Table 45: CFU analysis of antibiotic and tea concentrations 
on E. coli pre-formed biofilm 
 
Cells/mL Avg % Inhibition Std. Dev 
NC 55500 100 0 
PC 1880000 0 0 
E10 1100000 42.76186734 0.2178801 
E15 872000 55.11469881 2.7852796 
E30 1195000 37.51235835 0.6722059 
ES25 1095000 42.90672717 2.4811865 
ES50 1605000 14.97428134 2.0546025 
ES100 825000 57.73614868 1.8367225 
ES150 1085000 43.49461665 1.6497852 
ES200 1230000 35.64110132 0.3113487 
E10+ES25 1165000 39.23875556 1.0433062 
E10+ES50 1305000 31.53010006 0.3053735 
E10+ES100 970000 49.77081968 2.211664 
E10+ES150 845000 56.70945464 0.3847578 
E10+ES200 1080000 43.97491752 2.6593744 
E15+ES25 1315000 30.8303969 2.8621031 
E15+ES50 515000 74.91712811 2.1333466 
E15+ES100 335000 84.67917169 0.03265 
E15+ES150 220000 91.02991718 0.9628549 
E15+ES200 360000 83.32126168 0.2249222 
E30+ES25 500000 75.57533496 1.2917022 
E30+ES50 345000 84.12855344 0.0853595 
E30+ES100 335000 84.67917169 0.03265 
E30+ES150 825000 57.77341991 1.0580307 
E30+ES200 1275000 33.18195481 0.4635019 
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F. Confirmation of Inhibitory effect by Fluorescence microscopy 
  Fluorescence-based Live and Dead Assay was also conducted to 
qualitatively study the effects of combination treatments on pre-formed biofilm.  
Results for E. coli treated with multiple combinations are illustrated in Figure 83.  
The control sample had a green fluorescence indicating that the bacterial cells were 
alive.  On treatment, the cells emitting red fluorescence increased suggesting that 
the cells were no longer viable. Based on the microscopic images, the optimal 
combination concentration was determined to be E15+ES150 which further 
supported the CFU results.  
  In conclusion, the results of the CV assay, CFU viability study and 
bacterial viability assay indicate that EGCG-S at 200 ug/mL and 150 ug/mL has 
the highest synergistic effect on Erythromycin 10 ug/mL and 15 ug/mL for 
inhibiting biofilm formation and pre-formed biofilm respectively. These results are 
indicative of the potential synergism of antibiotic and tea polyphenol combination 
as an anti-biofilm agent. 
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Figure 83: Live and Dead Assay of E. coli pre-formed biofilm. (A) Control (B) with 
E15 (C) E100 and (D) E10+ES150 
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CONCLUSION 
 This study designates the potential of the combination of EGCG-S and antibiotics 
as an anti-biofilm agent in addition to being anti-bacterial compound. Combination of 
specific concentrations of EGCG-S and antibiotics are able to (i) inhibit biofilm 
formation and (ii) reduce pre-formed biofilm in six different potential pathogenic 
biofilms producing bacteria.  Bacterial cells individually treated with EGCG-S or 
antibiotics failed to inhibit biofilm. Additionally, the combination concentration 
exhibiting high level of inhibition on bacterial growth, for each organism, was unable to 
inhibit biofilm to about 90%. Previous studies conducted in the lab indicated that only 
EGCG-S, a modified form of EGCG, has the potential to supplement the action of 
antibiotics. Other green tea polyphenols failed to show maximum inhibition of bacterial 
growth owing to the differences in the structure and stability. Moreover, the study 
supported no dose-dependent effect of the combination of EGCG-S and antibiotic was 
observed on biofilm formation and pre-formed biofilm, indicating that use of lower 
concentrations of either antibiotic or tea polyphenol is possible to inhibit the biofilm 
effectively.  Furthermore, this study shows EGCG-S as potential broad spectrum anti-
bacterial agent as Gram positive, Gram negative and Acid-Fast bacteria were 
 The biofilm produced by each organism was subjected to multiple treatments to 
determine the LD50 and the optimal inhibitory combination concentration for suppressing 
the biofilm formation process and to reduce the pre-formed biofilm. The optimal 
combination concentration from the study is summarized in the following table: 
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Bacteria 
Biofilm Formation Pre-formed Biofilm 
Optimal 
Inhibitory 
concentration 
Percentage 
of 
Inhibition 
Optimal 
Inhibitory 
concentration 
Percentage 
of 
Reduction 
S. epidermidis TE15+ES250 98 TE15+ES250 95 
S. aureus TE15+ES200 96 TE30+ES100 95 
B. megaterium E10+ES100 98 E15+ES100 93 
P. aeruginosa E15+ES100 99 E15+ES150 95 
M. smegmatis E15+ES150 95 E30+ES100 92 
E. coli E10+ES200 95 E15+ES150 91 
 
 Based on the results obtained through this research, it is possible to state 
that EGCG-S has the potential in becoming an anti-biofilm agent by exhibiting 
synergistic co-operation with antibiotics since the optimal combination was able to 
effectively inhibit biofilm formation and reduce pre-formed biofilm.  This study 
highlights the anti-bacterial, anti-biofilm and synergistic action in the best possible 
manner.  These application studies provide promising results that would assist in 
combatting antibiotic resistance and biofilm problem effectively. 
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FUTURE STUDIES 
A significant future research would be to focus on the molecular mechanism 
aspect of EGCG. These studies would provide a better understanding of the effects of 
EGCG-S against bacterial biofilms. Anti-biofilm, anti-bacterial and synergism with 
antibiotics could be studied at molecular level to elucidate the mechanism of action. It 
will help us to identify the step/stage in the biofilm formation that is inhibited. This study 
could target specific gene, primarily responsible for biofilm production, and study their 
expression analysis when subjected to various single or combination treatments. These 
studies could more sensitively determine the best optimal combination and confidently 
ascertaining the potential of EGCG-S as an anti-biofilm and synergistic agent with 
antibiotics. 
Additionally, the knowledge about the mechanisms by virtue of which EGCG-S 
exerts its action is crucial in various medical application studies such as dental caries 
prevention and prosthetic joint infections treatment. Its action as an anti-spore agent is 
also being studied which could one day potentially be utilized in development of topical 
treatments, antiseptics, food preservatives etc. There might be a possibility of using 
antibiotics in combination with EGCG-S to negatively impact spore and biofilm 
formation. 
Generally, bacteria are rarely found in isolation plus the biofilms formed in 
infections are most of the time heterogeneous in nature. Thus, in future it is important to 
conduct a study using multiple bacteria found at an infection site in combination to 
resemble an in vivo environment. Moreover, a time-course study can also be performed to 
determine the duration for which effects of combination treatment lasts. 
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